{"id":"cabometyx","rwe":[{"pmid":"41826714","year":"2026","title":"A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats.","finding":"","journal":"Cancer chemotherapy and pharmacology","studyType":"Clinical Study"},{"pmid":"41555735","year":"2026","title":"Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.","finding":"","journal":"Health technology assessment (Winchester, England)","studyType":"Clinical Study"},{"pmid":"36743424","year":"2022","title":"Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma.","finding":"","journal":"Kidney cancer (Clifton, Va.)","studyType":"Clinical Study"}],"_fda":{"id":"03fee098-20c7-4a04-81a7-06fb7d8b1470","set_id":"1a0c3bea-c87b-4d25-bb44-5f0174da6b34","openfda":{"unii":["DR7ST46X58"],"route":["ORAL"],"rxcui":["1363273","1363279","1363281","1363284","1363312","1363408","1363409","1363410","1364580","1364581"],"spl_id":["03fee098-20c7-4a04-81a7-06fb7d8b1470"],"brand_name":["COMETRIQ"],"spl_set_id":["1a0c3bea-c87b-4d25-bb44-5f0174da6b34"],"package_ndc":["42388-011-14","42388-012-14","42388-013-14"],"product_ndc":["42388-011","42388-012","42388-013"],"generic_name":["CABOZANTINIB"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["CABOZANTINIB S-MALATE"],"manufacturer_name":["Exelixis, Inc."],"application_number":["NDA203756"],"is_original_packager":[true]},"version":"16","pregnancy":["8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, COMETRIQ can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform the drug-associated risk. In animal developmental and reproductive toxicology studies administration of cabozantinib to pregnant rats and rabbits during organogenesis resulted in embryofetal lethality and structural anomalies at exposures that were below those occurring clinically at the recommended dose (see Data ) . Advise pregnant women or women of childbearing potential of the potential hazard to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In an embryo-fetal development study in pregnant rats, daily oral administration of cabozantinib throughout organogenesis caused increased embryo-fetal lethality compared to controls at a dose of 0.03 mg/kg (less than 1% of the human exposure by AUC at the 140 mg dose). Findings included delayed ossifications and skeletal variations at a dose of 0.01 mg/kg/day (approximately 0.03% of the human exposure by AUC at the 140 mg dose). In pregnant rabbits, daily oral administration of cabozantinib throughout organogenesis resulted in findings of visceral malformations and variations including reduced spleen size and missing lung lobe at 3 mg/kg (approximately 11% of the human exposure by AUC at the 140 mg dose). In a pre- and postnatal study in rats, cabozantinib was administered orally from gestation day 10 through postnatal day 20. Cabozantinib did not produce adverse maternal toxicity or affect pregnancy, parturition or lactation of female rats, and did not affect the survival, growth or postnatal development of the offspring at doses up to 0.3 mg/kg/day (approximately 0.02 times the recommended clinical dose of 140 mg based on body surface area)."],"overdosage":["10 OVERDOSAGE One case of overdosage was reported in a patient who inadvertently took twice the intended dose (200 mg daily) for nine days. The patient suffered Grade 3 memory impairment, Grade 3 mental status changes, Grade 3 cognitive disturbance, Grade 2 weight loss, and Grade 1 increase in BUN. The extent of recovery was not documented."],"description":["11 DESCRIPTION COMETRIQ is the ( S )-malate salt of cabozantinib, a kinase inhibitor. Cabozantinib ( S )-malate is described chemically as N -(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)- N' -(4-fluorophenyl)cyclopropane- 1,1-dicarboxamide, (2 S )-hydroxybutanedioate. The molecular formula is C 28 H 24 FN 3 O 5 •C 4 H 6 O 5 and the molecular weight is 635.6 Daltons as malate salt. The chemical structure of cabozantinib ( S )-malate salt is: Cabozantinib ( S )-malate salt is a white to off-white solid that is practically insoluble in aqueous media. COMETRIQ (cabozantinib) capsules for oral use are supplied as printed hard gelatin capsules containing cabozantinib ( S )-malate equivalent to 20 mg or 80 mg cabozantinib and the following inactive ingredients: silicified microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, fumed silica, and stearic acid. The grey gelatin capsule shells contain black iron oxide and titanium dioxide and the Swedish orange gelatin capsule shells contain red iron oxide, and titanium dioxide. The printing ink contains shellac glaze, black iron oxide, N -butyl alcohol, isopropyl alcohol, propylene glycol, and ammonium hydroxide."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING COMETRIQ 20 mg capsules are supplied as hard gelatin capsules with grey cap and grey body, printed with \"XL184 20mg\" in black ink and containing cabozantinib ( S )-malate salt equivalent to 20 mg cabozantinib. COMETRIQ 80 mg capsules are supplied as hard gelatin capsules with Swedish orange cap and Swedish orange body, printed with \"XL184 80mg\" in black ink and containing cabozantinib ( S )- malate salt equivalent to 80 mg cabozantinib. COMETRIQ capsules are supplied as follows: Cartons 140 mg daily-dose carton NDC#42388-011-14 Containing four 140 mg daily-dose blister cards (each blister card contains seven 80-mg and twenty-one 20-mg capsules) 100 mg daily-dose carton NDC#42388-012-14 Containing four 100 mg daily-dose blister cards (each blister card contains seven 80-mg and seven 20-mg capsules) 60 mg daily-dose carton NDC#42388-013-14 Containing four 60 mg daily-dose blister cards (each blister card contains twenty-one 20-mg capsules) Store COMETRIQ at 20°C to 25°C (68°F to 77°F); excursions are permitted from 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]."],"geriatric_use":["8.5 Geriatric Use Clinical studies of COMETRIQ did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of COMETRIQ in pediatric patients have not been studied. Juvenile Animal Toxicity Data Juvenile rats were administered cabozantinib daily at doses of 1 or 2 mg/kg/day from Postnatal Day 12 (comparable to less than 2 years in humans) through Postnatal Day 35 or 70. Mortalities occurred at doses equal and greater than 1 mg/kg/day (approximately 0.07 times the clinical dose of 140 mg/day based on body surface area). Hypoactivity was observed at both doses tested on Postnatal Day 22. Targets were generally similar to those seen in adult animals, occurred at both doses, and included the kidney (nephropathy, glomerulonephritis), reproductive organs, gastrointestinal tract (cystic dilatation and hyperplasia in Brunner’s gland and inflammation of duodenum; and epithelial hyperplasia of colon and cecum), bone marrow (hypocellularity and lymphoid depletion), and liver. Tooth abnormalities and whitening as well as effects on bones including reduced bone mineral content and density, physeal hypertrophy, and decreased cortical bone also occurred at all dose levels. Recovery was not assessed at the 2 mg/kg dose level (approximately 0.14 times the clinical dose of 140 mg based on body surface area) due to high levels of mortality. At the low dose level, effects on bone parameters were partially resolved but effects on the kidney and epididymis/testis persisted after treatment ceased."],"effective_time":"20251018","nursing_mothers":["8.2 Lactation Risk Summary There is no information regarding the presence of cabozantinib or its metabolites in human milk, or their effects on the breastfed infant, or milk production. Because of the potential for serious adverse reactions in a breastfed infant from COMETRIQ, advise a lactating woman not to breastfeed during treatment with COMETRIQ and for 4 months after the final dose."],"clinical_studies":["14 CLINICAL STUDIES The safety and efficacy of COMETRIQ was assessed in an international, multi-center, randomized, double-blind, controlled trial (Study 1) of 330 patients with metastatic medullary thyroid carcinoma (MTC). Patients were required to have evidence of actively progressive disease within 14 months prior to study entry confirmed by an Independent Radiology Review Committee (IRRC) masked to treatment assignment (89%) or the treating physician (11%). Patients were randomized (2:1) to receive COMETRIQ 140 mg (n = 219) or placebo (n = 111) orally once daily, without food, until disease progression determined by the treating physician or until intolerable toxicity. Randomization was stratified by age (≤ 65 years vs. > 65 years) and prior use of a tyrosine kinase inhibitor (TKI) (yes vs. no). No cross-over was allowed at the time of progression. The main efficacy outcome measures of progression-free survival (PFS), objective response (OR), and response duration were based on IRRC-confirmed events using modified RECIST criteria. Of 330 patients randomized, 67% were male, the median age was 55 years, 23% were 65 years or older, 89% were white, 54% had a baseline ECOG performance status of 0, and 92% had undergone a thyroidectomy. The RET mutation status determined by a research-use assay was positive in 51%, negative in 14%, and was unknown in 35%. Twenty-five percent (25%) had two or more prior systemic therapies and 21% had been previously treated with a TKI. A statistically significant prolongation in PFS was demonstrated among COMETRIQ-treated patients compared to those receiving placebo [HR 0.28 (95% CI: 0.19, 0.40); p<0.0001], with median PFS times of 11.2 months and 4.0 months in the COMETRIQ and placebo arms, respectively. Partial responses were observed only among patients in the COMETRIQ arm (27% vs. 0; p<0.0001). The median duration of objective responses was 14.7 months (95% CI: 11.1, 19.3) for patients treated with COMETRIQ. There was no statistically significant difference in overall survival (median OS: 26.6 months in the COMETRIQ arm vs. 21.1 months in the placebo arm [HR = 0.85 (95% CI: 0.64, 1.12), p = 0.2409]). Figure 1: Progression-Free Survival"],"pharmacodynamics":["12.2 Pharmacodynamics Cardiac Electrophysiology The effect of orally administered COMETRIQ 140 mg on QTc interval was evaluated in a randomized, double-blinded, placebo-controlled study in patients with MTC. A mean increase in QTcF of 10 - 15 ms was observed at 4 weeks after initiating COMETRIQ. A concentration-QTc relationship could not be definitively established. Changes in cardiac wave form morphology or new rhythms were not observed. No COMETRIQ-treated patients had a QTcF > 500 ms [see Clinical Studies (14) ] ."],"pharmacokinetics":["12.3 Pharmacokinetics A population pharmacokinetic analysis of cabozantinib was performed using data collected from 289 patients with solid tumors including MTC following oral administration of 140 mg daily doses. Repeat daily dosing of COMETRIQ at 140 mg for 19 days resulted in 4- to 5-fold mean cabozantinib accumulation (based on AUC) compared to a single dose administration; steady state was achieved by Day 15. Absorption Following oral administration of COMETRIQ, median time to peak cabozantinib plasma concentrations (T max ) ranged from 2 to 5 hours post-dose. A 19% increase in the C max of the tablet formulation (CABOMETYX ™ ) compared to the capsule formulation (COMETRIQ) was observed following a single 140 mg dose. A less than 10% difference in the AUC was observed between cabozantinib tablet (CABOMETYX) and capsule (COMETRIQ) formulations [see Dosage and Administration ( 2.1 )] . Cabozantinib C max and AUC values increased by 41% and 57%, respectively, following a high-fat meal relative to fasted conditions in healthy subjects administered a single 140 mg oral COMETRIQ dose. Distribution The oral volume of distribution (V/F) of cabozantinib is approximately 349 L. Cabozantinib is highly protein bound in human plasma (≥ 99.7%). Elimination The predicted effective half-life is approximately 55 hours and the clearance (CL/F) at steady-state is estimated to be 4.4 L/hr. Metabolism Cabozantinib is a substrate of CYP3A4 in vitro . Excretion Approximately 81% of the total administered radioactivity was recovered within a 48-day collection period following a single 140 mg dose of an investigational 14 C-cabozantinib formulation in healthy subjects. Approximately 54% was recovered in feces and 27% in urine. Unchanged cabozantinib accounted for 43% of the total radioactivity in feces and was not detectable in urine following a 72 hour collection. Specific Populations The following patient characteristics did not result in a clinically relevant difference in the pharmacokinetics of cabozantinib: age (20-86 years), sex, race (Whites and non-Whites), or mild to moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73 m 2 as estimated by MDRD (modification of diet in renal disease equation)). The pharmacokinetics of cabozantinib is unknown in patients with worse than moderate renal impairment (eGFR less than 29 mL/min/1.73m 2 ) as estimated by MDRD equation or renal impairment requiring dialysis. Patients with Hepatic Impairment Following a single oral 60 mg COMETRIQ, mean AUC 0-inf for cabozantinib increased by 81% in subjects with mild (Child-Pugh A) hepatic impairment and 63% in subjects with moderate (Child-Pugh B) hepatic impairment compared to subjects with normal hepatic function [see Dosage and Administration (2.5) , Use in Specific Populations (8.6) ] . The pharmacokinetics of cabozantinib has not been studied in patients with severe (Child-Pugh C) hepatic impairment [see Use in Specific Populations (8.6) ] . Drug Interaction Studies CYP3A4 Inhibition on Cabozantinib Administration of a strong CYP3A4 inhibitor, ketoconazole (400 mg daily for 27 days) to healthy subjects increased single-dose plasma cabozantinib exposure (AUC 0-inf ) by 38%. CYP3A4 Induction on Cabozantinib Administration of a strong CYP3A4 inducer, rifampin (600 mg daily for 31 days) to healthy subjects decreased single-dose plasma cabozantinib exposure (AUC 0-inf ) by 77%. Cabozantinib on CYP2C8 substrates No clinically-significant effect on single-dose rosiglitazone (a CYP2C8 substrate) plasma exposure (C max and AUC) was observed when co-administered with cabozantinib at steady-state plasma concentrations (≥ 100 mg/day daily for a minimum of 21 days) in patients with solid tumors. Gastric pH modifying agents on Cabozantinib No clinically-significant effect on plasma cabozantinib exposure (AUC) was observed following co-administration of the proton pump inhibitor (PPI) esomeprazole (40 mg daily for 6 days) with a single dose of 100 mg cabozantinib to healthy volunteers. In vitro Studies Metabolic Pathways: Inhibition of CYP3A4 reduced the formation of the XL184 N -oxide metabolite by >80%. Inhibition of CYP2C9 had a minimal effect on cabozantinib metabolite formation (i.e., a <20% reduction). Inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP2E1 had no effect on cabozantinib metabolite formation. Although cabozantinib is an inhibitor of CYP2C8 in vitro , a clinical study of this potential interaction concluded that concurrent use did not result in a clinically relevant effect on CYP2C8 substrate exposure. Given this finding, other less sensitive substrates of pathways affected by cabozantinib in vitro (i.e., CYP2C9, CYP2C19, and CYP3A4) were not evaluated in a clinical study because, although a clinically relevant exposure effect cannot be ruled out, it is unlikely. Cabozantinib does not inhibit CYP1A2 and CYP2D6 isozymes in vitro . Cabozantinib is an inducer of CYP1A1 mRNA; however, the clinical relevance of this finding is unknown. Cabozantinib does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP3A4. Drug Transporter Systems: Cabozantinib is an inhibitor, but not a substrate, of P-gp transport activities and has the potential to increase plasma concentrations of co-administered substrates of P-gp. The clinical relevance of this finding is unknown. Cabozantinib is a substrate of MRP2 in vitro and MRP2 inhibitors have the potential to increase plasma concentrations of cabozantinib. The clinical relevance of this finding is unknown."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed elsewhere in the labeling: Perforations and Fistula [see Warnings and Precautions (5.1) ] Hemorrhage [see Warnings and Precautions (5.2) ] Thromboembolic Events [see Warnings and Precautions (5.3) ] Impaired Wound Healing [see Warnings and Precautions (5.4) ] Hypertension and Hypertensive Crisis [see Warnings and Precautions (5.5) ] Cardiac Failure [see Warnings and Precautions (5.6) ] Osteonecrosis of the Jaw [see Warnings and Precautions (5.7) ] Diarrhea [see Warnings and Precautions (5.8) ] Palmar-Plantar Erythrodysesthesia [see Warnings and Precautions (5.9) ] Proteinuria [see Warnings and Precautions (5.10) ] Reversible Posterior Leukoencephalopathy Syndrome [see Warnings and Precautions (5.11) ] Hypocalcemia [see Warnings and Precautions (5.13) ] The most common adverse reactions (≥ 25%) are diarrhea, stomatitis, palmar-plantar erythrodysesthesia (PPE), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation. The most common laboratory abnormalities (≥ 25%) are increased AST, increased ALT, lymphopenia, increased alkaline phosphatase, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Exelixis, Inc. at 1-855-500-3935 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trial Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of COMETRIQ was evaluated in 330 patients with progressive metastatic medullary thyroid cancer randomized to receive 140 mg COMETRIQ (n = 214) or placebo (n = 109) administered daily until disease progression or intolerable toxicity in a randomized, doubleblind, controlled trial (Study 1) [see Clinical Studies ( 14 )] . The data described below reflect a median exposure to COMETRIQ for 204 days. The population exposed to COMETRIQ was 70% male, 90% white, and had a median age of 55 years. Fatal adverse reactions occurred in 6% of patients receiving COMETRIQ and resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death. Fatal adverse reactions occurred in 5% of patients receiving placebo and resulted from septicemia, pneumonia, and general deterioration. The COMETRIQ dose was reduced in 79% of patients receiving COMETRIQ and in 9% of patients receiving placebo. The median number of dosing delays was one in patients receiving COMETRIQ and in no patients receiving placebo. Adverse reactions led to study treatment discontinuation in 16% of patients receiving COMETRIQ. The most frequent adverse reactions leading to permanent discontinuation of COMETRIQ were: hypocalcemia, increased lipase, PPE, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting. Increased levels of thyroid stimulating hormone (TSH) were observed in 57% of patients receiving COMETRIQ after the first dose compared to 19% of patients receiving placebo (regardless of baseline value). Ninety-two percent (92%) of patients on the COMETRIQ arm had a prior thyroidectomy, and 89% were taking thyroid hormone replacement prior to the first dose. Adverse reactions which occurred in ≥ 25% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of ≥ 5% included, in order of decreasing frequency: diarrhea, stomatitis, palmar-plantar erythrodysesthesia (PPE), decreased weight, decreased appetite, nausea, fatigue, oral pain, hair color changes, dysgeusia, hypertension, abdominal pain, and constipation. The most common laboratory abnormalities (≥25%) were increased AST, increased ALT, lymphopenia, increased ALP, hypocalcemia, neutropenia, thrombocytopenia, hypophosphatemia, and hyperbilirubinemia. Grade 3-4 adverse reactions and laboratory abnormalities which occurred in ≥ 5% of COMETRIQ-treated patients occurring more frequently in the COMETRIQ arm with a between-arm difference of ≥ 2% included, in order of decreasing frequency; diarrhea, PPES, lymphopenia, hypocalcemia, fatigue, hypertension, asthenia, increased ALT, decreased weight, stomatitis, and decreased appetite ( Table 1 and Table 2 summarize the adverse reactions and laboratory abnormalities reported in Study 1). Table 1. Selected Adverse Reactions Occurring at a Higher Incidence in COMETRIQ-Treated Patients (Study 1) [Between Arm Difference of ≥ 5% (All Grades) National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 or ≥ 2% (Grades 3-4)] System Organ Class/Preferred Terms COMETRIQ (n=214) Placebo (n=109) All Grades (%) Grades 3-4 (%) All Grades (%) Grades 3-4 (%) GASTROINTESTINAL DISORDERS Diarrhea 63 16 33 2 Stomatitis Includes the following terms: stomatitis, aphthous stomatitis, mouth ulceration, mucosal inflammation 51 5 6 0 Nausea 43 1 21 0 Oral pain Includes the following terms: oral pain, oropharyngeal pain, glossitis, burning mouth syndrome, glossodynia 36 2 6 0 Constipation 27 0 6 0 Abdominal pain Includes the following terms: abdominal pain, abdominal pain lower, abdominal pain upper, abdominal rigidity, abdominal tenderness, esophageal pain 27 3 13 1 Vomiting 24 2 2 1 Dysphagia 13 4 6 1 Dyspepsia 11 0 0 0 Hemorrhoids 9 0 3 0 SKIN AND SUBCUTANEOUS TISSUE DISORDERS PPE Palmar-plantar erythrodysesthesia 50 13 2 0 Hair color changes/ depigmentation, graying 34 0 1 0 Rash 19 1 10 0 Dry skin 19 0 3 0 Alopecia 16 0 2 0 Erythema 11 1 2 0 Hyperkeratosis 7 0 0 0 INVESTIGATIONS Decreased weight 48 5 10 0 METABOLISM AND NUTRITION DISORDERS Decreased appetite 46 5 16 1 Dehydration 7 2 2 1 GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS Fatigue 41 9 28 3 Asthenia 21 6 15 1 NERVOUS SYSTEM DISORDERS Dysgeusia 34 0 6 0 Headache 18 0 8 0 Dizziness 14 0 7 0 Paresthesia 7 0 2 0 Peripheral sensory neuropathy 7 0 0 0 Peripheral neuropathy 5 0 0 0 VASCULAR DISORDERS Hypertension 33 8 4 0 Hypotension 7 1 0 0 RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS Dysphonia 20 0 9 0 MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS Arthralgia 14 1 7 0 Muscle spasms 12 0 5 0 Musculoskeletal chest pain 9 1 4 0 PSYCHIATRIC DISORDERS Anxiety 9 0 2 0 Table 2 Laboratory Abnormalities Occurring at a Higher Incidence in COMETRIQ-Treated Patients (Study 1) [Between Arm Difference of ≥ 5% (All Grades) or ≥ 2% (Grades 3-4)] Test COMETRIQ (n=214) Placebo (N=109) All Grades (%) Grade 3-4 (%) All Grades (%) Grade 3-4 (%) Chemistries Increased AST 86 3 35 2 Increased ALT 86 6 41 2 Increased ALP 52 3 35 3 Hypocalcemia 52 12 27 3 Hypoalbuminemia 43 2 16 0 Hypophosphatemia 28 3 10 1 Hyperbilirubinemia 25 2 14 5 Hypomagnesemia 19 1 4 0 Hypokalemia 18 4 9 3 Hyponatremia 10 2 5 0 Hematologic Lymphopenia 53 16 51 11 Neutropenia 35 3 15 2 Thrombocytopenia 35 0 4 3 ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase Nearly all COMETRIQ-treated patients (96% vs. 84% placebo) experienced elevated blood pressure and there was a doubling in the incidence of overt hypertension in COMETRIQ-treated patients over placebo-treated patients (61% vs. 30%) according to modified Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC) staging criteria. No patients developed malignant hypertension. Table 3 Per-Patient Incidence of Hypertension (Study 1) Hypertension, JNC Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA 2003: 289:2560. Criteria applied were modified, as multiple readings were not available per timepoint, and therefore not averaged. Stage Patients classified by highest category based on all recorded blood pressure readings beginning after the first dose through 30 days after last dose. COMETRIQ N=211 Patients with at least two blood pressure measurements after the first dose (%) Placebo N=107 (%) Normal: Grade 0: Systolic < 120 mmHg and Diastolic < 80 mmHg 4 15 Pre-hypertension: Systolic ≥ 120 mmHg or Diastolic ≥ 80 mmHg 34 54 Stage 1: Systolic ≥ 140 mmHg or Diastolic ≥ 90 mmHg 46 25 Stage 2: Systolic ≥ 160 mmHg or Diastolic ≥ 100 mmHg 15 5 Malignant: Diastolic ≥ 120 mmHg 0 0 Other clinically important adverse reactions (all grades) that were reported in clinical trials include: hepatitis cholestatic (<1%). 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of COMETRIQ. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Hematology: A case of supratherapeutic international normalized ratio (INR) and epistaxis during concomitant use of warfarin Musculoskeletal and Connective Tissue Disorders: Extremity pain Vascular Disorders: Arterial (including aortic) aneurysms, dissections, and rupture"],"contraindications":["4 CONTRAINDICATIONS None None. ( 4 )"],"drug_interactions":["7 DRUG INTERACTIONS Strong CYP3A4 Inhibitors: Reduce the COMETRIQ dosage. ( 2.2 , 7.1 ) Strong CYP3A4 Inducers: Increase the COMETRIQ dosage. ( 2.2 , 7.2 ) 7.1 Effect of CYP3A4 Inhibitors Administration of a strong CYP3A4 inhibitor, ketoconazole to healthy subjects increased single-dose plasma cabozantinib exposure by 38%. Avoid taking a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole) while taking COMETRIQ or reduce the dosage of COMETRIQ if concomitant use with strong CYP3A4 inhibitors cannot be avoided [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )] . Avoid ingestion of foods (e.g., grapefruit, grapefruit juice) or nutritional supplements that are known to inhibit cytochrome P450 while taking COMETRIQ. 7.2 Effect of CYP3A4 Inducers Administration of a strong CYP3A4 inducer, rifampin to healthy subjects decreased single-dose plasma cabozantinib exposure by 77%. Avoid chronic co-administration of strong CYP3A4 inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John’s Wort) with COMETRIQ or increase the dosage of COMETRIQ if concomitant use with strong CYP3A4 inducers cannot be avoided [see Dosage and Administration ( 2.2 ), Clinical Pharmacology ( 12.3 )]. 7.3 Effect of MRP2 Inhibitors Concomitant administration of MRP2 inhibitors may increase the exposure to cabozantinib. Monitor patients for increased toxicity when MRP2 inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudine, nevirapine, ritonavir, probenecid, saquinavir, and tenofovir) are co-administered with COMETRIQ [see Clinical Pharmacology ( 12.3 )] ."],"mechanism_of_action":["12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment."],"recent_major_changes":["Warnings and Precautions ( 5.6 ) 10/2025"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment. 12.2 Pharmacodynamics Cardiac Electrophysiology The effect of orally administered COMETRIQ 140 mg on QTc interval was evaluated in a randomized, double-blinded, placebo-controlled study in patients with MTC. A mean increase in QTcF of 10 - 15 ms was observed at 4 weeks after initiating COMETRIQ. A concentration-QTc relationship could not be definitively established. Changes in cardiac wave form morphology or new rhythms were not observed. No COMETRIQ-treated patients had a QTcF > 500 ms [see Clinical Studies (14) ] . 12.3 Pharmacokinetics A population pharmacokinetic analysis of cabozantinib was performed using data collected from 289 patients with solid tumors including MTC following oral administration of 140 mg daily doses. Repeat daily dosing of COMETRIQ at 140 mg for 19 days resulted in 4- to 5-fold mean cabozantinib accumulation (based on AUC) compared to a single dose administration; steady state was achieved by Day 15. Absorption Following oral administration of COMETRIQ, median time to peak cabozantinib plasma concentrations (T max ) ranged from 2 to 5 hours post-dose. A 19% increase in the C max of the tablet formulation (CABOMETYX ™ ) compared to the capsule formulation (COMETRIQ) was observed following a single 140 mg dose. A less than 10% difference in the AUC was observed between cabozantinib tablet (CABOMETYX) and capsule (COMETRIQ) formulations [see Dosage and Administration ( 2.1 )] . Cabozantinib C max and AUC values increased by 41% and 57%, respectively, following a high-fat meal relative to fasted conditions in healthy subjects administered a single 140 mg oral COMETRIQ dose. Distribution The oral volume of distribution (V/F) of cabozantinib is approximately 349 L. Cabozantinib is highly protein bound in human plasma (≥ 99.7%). Elimination The predicted effective half-life is approximately 55 hours and the clearance (CL/F) at steady-state is estimated to be 4.4 L/hr. Metabolism Cabozantinib is a substrate of CYP3A4 in vitro . Excretion Approximately 81% of the total administered radioactivity was recovered within a 48-day collection period following a single 140 mg dose of an investigational 14 C-cabozantinib formulation in healthy subjects. Approximately 54% was recovered in feces and 27% in urine. Unchanged cabozantinib accounted for 43% of the total radioactivity in feces and was not detectable in urine following a 72 hour collection. Specific Populations The following patient characteristics did not result in a clinically relevant difference in the pharmacokinetics of cabozantinib: age (20-86 years), sex, race (Whites and non-Whites), or mild to moderate renal impairment (eGFR greater than or equal to 30 mL/min/1.73 m 2 as estimated by MDRD (modification of diet in renal disease equation)). The pharmacokinetics of cabozantinib is unknown in patients with worse than moderate renal impairment (eGFR less than 29 mL/min/1.73m 2 ) as estimated by MDRD equation or renal impairment requiring dialysis. Patients with Hepatic Impairment Following a single oral 60 mg COMETRIQ, mean AUC 0-inf for cabozantinib increased by 81% in subjects with mild (Child-Pugh A) hepatic impairment and 63% in subjects with moderate (Child-Pugh B) hepatic impairment compared to subjects with normal hepatic function [see Dosage and Administration (2.5) , Use in Specific Populations (8.6) ] . The pharmacokinetics of cabozantinib has not been studied in patients with severe (Child-Pugh C) hepatic impairment [see Use in Specific Populations (8.6) ] . Drug Interaction Studies CYP3A4 Inhibition on Cabozantinib Administration of a strong CYP3A4 inhibitor, ketoconazole (400 mg daily for 27 days) to healthy subjects increased single-dose plasma cabozantinib exposure (AUC 0-inf ) by 38%. CYP3A4 Induction on Cabozantinib Administration of a strong CYP3A4 inducer, rifampin (600 mg daily for 31 days) to healthy subjects decreased single-dose plasma cabozantinib exposure (AUC 0-inf ) by 77%. Cabozantinib on CYP2C8 substrates No clinically-significant effect on single-dose rosiglitazone (a CYP2C8 substrate) plasma exposure (C max and AUC) was observed when co-administered with cabozantinib at steady-state plasma concentrations (≥ 100 mg/day daily for a minimum of 21 days) in patients with solid tumors. Gastric pH modifying agents on Cabozantinib No clinically-significant effect on plasma cabozantinib exposure (AUC) was observed following co-administration of the proton pump inhibitor (PPI) esomeprazole (40 mg daily for 6 days) with a single dose of 100 mg cabozantinib to healthy volunteers. In vitro Studies Metabolic Pathways: Inhibition of CYP3A4 reduced the formation of the XL184 N -oxide metabolite by >80%. Inhibition of CYP2C9 had a minimal effect on cabozantinib metabolite formation (i.e., a <20% reduction). Inhibition of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C19, CYP2D6 and CYP2E1 had no effect on cabozantinib metabolite formation. Although cabozantinib is an inhibitor of CYP2C8 in vitro , a clinical study of this potential interaction concluded that concurrent use did not result in a clinically relevant effect on CYP2C8 substrate exposure. Given this finding, other less sensitive substrates of pathways affected by cabozantinib in vitro (i.e., CYP2C9, CYP2C19, and CYP3A4) were not evaluated in a clinical study because, although a clinically relevant exposure effect cannot be ruled out, it is unlikely. Cabozantinib does not inhibit CYP1A2 and CYP2D6 isozymes in vitro . Cabozantinib is an inducer of CYP1A1 mRNA; however, the clinical relevance of this finding is unknown. Cabozantinib does not induce CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19 or CYP3A4. Drug Transporter Systems: Cabozantinib is an inhibitor, but not a substrate, of P-gp transport activities and has the potential to increase plasma concentrations of co-administered substrates of P-gp. The clinical relevance of this finding is unknown. Cabozantinib is a substrate of MRP2 in vitro and MRP2 inhibitors have the potential to increase plasma concentrations of cabozantinib. The clinical relevance of this finding is unknown."],"indications_and_usage":["1 INDICATIONS AND USAGE COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). COMETRIQ is a kinase inhibitor indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC). ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Perforations and Fistulas: Monitor for symptoms. Discontinue COMETRIQ for Grade 4 fistula or perforation. ( 5.1 ) Hemorrhage: Do not administer COMETRIQ if recent history of hemorrhage. ( 5.2 ) Thrombotic Events: Discontinue COMETRIQ for myocardial infarction or serious arterial or venous thromboembolic events. ( 5.3 ) Impaired Wound Healing: Withhold COMETRIQ for at least 3 weeks before elective surgery. Do not administer for at least 2 weeks following major surgery and until adequate wound healing. The safety of resumption of COMETRIQ after resolution of wound healing complications has not been established. ( 5.4 ) Hypertension and hypertensive crisis: Monitor blood pressure regularly. Interrupt for hypertension that is not adequately controlled with anti- hypertensive therapy. Discontinue COMETRIQ for hypertensive crisis or severe hypertension that cannot be controlled with anti-hypertensive therapy. ( 5.5 ) Cardiac Failure: Monitor patients for signs and symptoms of cardiac failure throughout treatment. ( 5.6 ) Osteonecrosis of the Jaw (ONJ): Withhold COMETRIQ for at least 3 weeks prior to invasive dental procedure and for development of ONJ. ( 5.7 ) Diarrhea: May be severe. Interrupt COMETRIQ immediately until diarrhea resolves or decreases to Grade 1. Recommend standard antidiarrheal treatments. ( 5.8 ) Palmar-Plantar Erythrodysesthesia (PPE): Interrupt COMETRIQ until PPE resolves or decreases to Grade 1. ( 5.9 ) Proteinuria: Monitor urine protein. Discontinue for nephrotic syndrome. ( 5.10 ) Reversible Posterior Leukoencephalopathy Syndrome (RPLS): Discontinue COMETRIQ. ( 5.11 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception. ( 5.12 , 8.1 , 8.3 ) Hypocalcemia: Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold COMETRIQ and resume at reduced dose upon recovery or permanently discontinue COMETRIQ depending on severity. ( 5.13 ) 5.1 Perforations and Fistulas Gastrointestinal (GI) perforations and fistulas, including fatal cases, were reported in 3% and 1% of COMETRIQ-treated patients (N=214), respectively. Non-GI fistulas including tracheal/esophageal, including fatal cases, were reported in 4% of COMETRIQ-treated patients. Monitor patients for symptoms of perforations and fistulas, including abscess and sepsis. Discontinue COMETRIQ in patients who experience a Grade 4 fistula or a GI perforation [see Dosage and Administration (2.2) ] . 5.2 Hemorrhage Severe and fatal hemorrhage occurred with COMETRIQ. The incidence of Grade ≥ 3 hemorrhagic events was higher in COMETRIQ-treated patients compared with placebo (3% vs. 1%). Discontinue COMETRIQ for Grade 3 or 4 hemorrhage [see Dosage and Administration (2.2) ] . Do not administer COMETRIQ to patients with a recent history of hemorrhage, including hemoptysis, hematemesis, or melena. 5.3 Thromboembolic Events COMETRIQ increased the incidence of thrombotic events (venous thromboembolism: 6% vs. 3% and arterial thromboembolism: 2% vs. 0% in COMETRIQ-treated and placebo-treated patients, respectively). Discontinue COMETRIQ in patients who develop an acute myocardial infarction or arterial or venous thromboembolic events that require medical intervention [see Dosage and Administration (2.2) ] . 5.4 Impaired Wound Healing Wound complications have been reported with COMETRIQ. Withhold COMETRIQ for at least 3 weeks prior to elective surgery. Do not administer COMETRIQ for at least 2 weeks after major surgery and until adequate wound healing. The safety of resumption of COMETRIQ after resolution of wound healing complications has not been established. 5.5 Hypertension and Hypertensive Crisis COMETRIQ can cause hypertension, including hypertensive crisis. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (modified JNC criteria) stage 1 or 2 hypertension was identified in 61% in COMETRIQ-treated patients compared with 30% of placebo-treated patients in the randomized trial [see Adverse Reactions (6.1) ] . Do not initiate COMETRIQ in patients with uncontrolled hypertension. Monitor blood pressure regularly during COMETRIQ treatment. Withhold COMETRIQ for hypertension that is not adequately controlled with medical management; when controlled, resume COMETRIQ at a reduced dose. Discontinue COMETRIQ for severe hypertension that cannot be controlled with anti-hypertensive therapy and for hypertensive crisis [see Dosage and Administration (2.2) ] . 5.6 Cardiac Failure COMETRIQ can cause severe and fatal cardiac failure [see Adverse Reactions (6.1) ] . Cardiac failure occurred in 0.9% of patients treated with COMETRIQ as a single agent. Median time to onset of cardiac failure was 76 days (range: 60 days to 92 days). Consider baseline and periodic evaluations of left ventricular ejection fraction. Monitor for signs and symptoms of cardiovascular events. Withhold and resume at a reduced dose upon recovery or permanently discontinue COMETRIQ depending on the severity [see Dosage and Administration (2.2) ] . 5.7 Osteonecrosis of the Jaw Osteonecrosis of the jaw (ONJ) occurred in 1% of COMETRIQ-treated patients. ONJ can manifest as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration or erosion, persistent jaw pain or slow healing of the mouth or jaw after dental surgery. Perform an oral examination prior to initiation of COMETRIQ and periodically during COMETRIQ therapy. Advise patients regarding good oral hygiene practices. Withhold COMETRIQ treatment for at least 3 weeks prior to scheduled dental surgery, or invasive dental procedures, if possible. Withhold COMETRIQ for development of ONJ until complete resolution [see Dosage and Administration (2.2) ] . 5.8 Diarrhea Diarrhea occurred in 63% of patients treated with COMETRIQ. Grade 3-4 diarrhea occurred in 16% of patients treated with COMETRIQ [see Adverse Reactions (6.1) ] . Withhold COMETRIQ until improvement to Grade 1 and resume COMETRIQ at a reduced dose for intolerable Grade 2 diarrhea, Grade 3 diarrhea that cannot be managed with standard antidiarrheal treatments, or Grade 4 diarrhea. 5.9 Palmar-Plantar Erythrodysesthesia Palmar-plantar erythrodysesthesia (PPE) occurred in 50% of patients treated with COMETRIQ, including 13% Grade 3 [see Adverse Reactions (6.1) ] . Withhold COMETRIQ until improvement to Grade 1 and resume COMETRIQ at a reduced dose for intolerable Grade 2 PPE or Grade 3 PPE. 5.10 Proteinuria Proteinuria was observed in 2% of patients receiving COMETRIQ, including one with nephrotic syndrome. Monitor urine protein regularly during COMETRIQ treatment. Discontinue COMETRIQ in patients who develop nephrotic syndrome. 5.11 Reversible Posterior Leukoencephalopathy Syndrome Reversible Posterior Leukoencephalopathy Syndrome (RPLS), a syndrome of subcortical vasogenic edema diagnosed by characteristic finding on MRI, occurred in one (<1%) patient. Perform an evaluation for RPLS in any patient presenting with seizures, headache, visual disturbances, confusion or altered mental function. Discontinue COMETRIQ in patients who develop RPLS [see Dosage and Administration (2.2) ] . 5.12 Embryo-Fetal Toxicity Based on data from animal studies and its mechanism of action, COMETRIQ can cause fetal harm when administered to a pregnant woman. Cabozantinib administration to pregnant animals during organogenesis resulted in embryolethality at exposures below those occurring clinically at the recommended dose, and in increased incidences of skeletal variations in rats and visceral variations and malformations in rabbits. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with COMETRIQ and for 4 months after the last dose [see Use in Specific Populations ( 8.1 ), ( 8.3 ), and Clinical Pharmacology ( 12.1 )] . 5.13 Hypocalcemia COMETRIQ can cause hypocalcemia. Based on the safety population [see Clinical Trial Experience ( 6.1 )] , hypocalcemia occurred in 52% of patients treated with COMETRIQ, including Grade 3 or 4 in 12% of patients. Monitor blood calcium levels and replace calcium as necessary during treatment. Withhold and resume at a reduced dose upon recovery or discontinue COMETRIQ depending on severity [see Dosage and Administration ( 2.2 )] ."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of cabozantinib has been evaluated in two species: rasH2 transgenic mice and Sprague-Dawley rats. In the 2-year rat carcinogenicity study, once daily oral administration of cabozantinib resulted in a statistically significant increase in the incidence of malignant/complex malignant pheochromocytoma in combination with benign pheochromocytoma or in benign pheochromocytoma alone in male rats at a dose of 1 mg/kg (approximately 0.6 times the human exposure by AUC at the recommended 140 mg dose). Cabozantinib was not carcinogenic in a 26-week carcinogenicity study in rasH2 transgenic mice at a slightly higher exposure than the intended human therapeutic exposure. Cabozantinib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay and was not clastogenic in both the in vitro cytogenetic assay using human lymphocytes or in the in vivo mouse micronucleus assay. Based on nonclinical findings, male and female fertility may be impaired by treatment with COMETRIQ. In a fertility study in which cabozantinib was administered to male and female rats at doses of 1, 2.5, and 5 mg/kg/day, male fertility was significantly compromised at doses equal to or greater than 2.5 mg/kg/day (approximately equal to the human exposure by AUC at the recommended dose), with a decrease in sperm counts and reproductive organ weights. In females, fertility was significantly reduced at doses equal to or greater than 1 mg/kg/day (approximately 50% of the human exposure by AUC at the 140 mg recommended dose) with a significant decrease in the number of live embryos and a significant increase in pre- and post-implantation losses. Observations of effects on reproductive tract tissues in general toxicology studies were supportive of effects noted in the dedicated fertility study and included hypospermia and absence of corpora lutea in male and female dogs in a 6-month repeat dose study at exposures equal to 6% and 3%, respectively, the human exposure by AUC at the recommended dose. In addition, female rats administered 5 mg/kg/day for 14 days (approximately equal to the human exposure by AUC at the 140 mg recommended dose) exhibited ovarian necrosis."],"adverse_reactions_table":["
Table 1. Selected Adverse Reactions Occurring at a Higher Incidence in COMETRIQ-Treated Patients (Study 1) [Between Arm Difference of ≥ 5% (All Grades)National Cancer Institute Common Terminology Criteria for Adverse Events Version 3.0 or ≥ 2% (Grades 3-4)]
System Organ Class/Preferred TermsCOMETRIQ (n=214)Placebo (n=109)
All Grades (%)Grades 3-4 (%)All Grades (%)Grades 3-4 (%)
GASTROINTESTINAL DISORDERS
Diarrhea6316332
StomatitisIncludes the following terms: stomatitis, aphthous stomatitis, mouth ulceration, mucosal inflammation51560
Nausea431210
Oral painIncludes the following terms: oral pain, oropharyngeal pain, glossitis, burning mouth syndrome, glossodynia36260
Constipation27060
Abdominal painIncludes the following terms: abdominal pain, abdominal pain lower, abdominal pain upper, abdominal rigidity, abdominal tenderness, esophageal pain273131
Vomiting24221
Dysphagia13461
Dyspepsia11000
Hemorrhoids9030
SKIN AND SUBCUTANEOUS TISSUE DISORDERS
PPEPalmar-plantar erythrodysesthesia501320
Hair color changes/ depigmentation, graying34010
Rash191100
Dry skin19030
Alopecia16020
Erythema11120
Hyperkeratosis7000
INVESTIGATIONS
Decreased weight485100
METABOLISM AND NUTRITION DISORDERS
Decreased appetite465161
Dehydration7221
GENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS
Fatigue419283
Asthenia216151
NERVOUS SYSTEM DISORDERS
Dysgeusia34060
Headache18080
Dizziness14070
Paresthesia7020
Peripheral sensory neuropathy7000
Peripheral neuropathy5000
VASCULAR DISORDERS
Hypertension33840
Hypotension7100
RESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS
Dysphonia20090
MUSCULOSKELETAL AND CONNECTIVE TISSUE DISORDERS
Arthralgia14170
Muscle spasms12050
Musculoskeletal chest pain9140
PSYCHIATRIC DISORDERS
Anxiety9020
","
Table 2 Laboratory Abnormalities Occurring at a Higher Incidence in COMETRIQ-Treated Patients (Study 1) [Between Arm Difference of ≥ 5% (All Grades) or ≥ 2% (Grades 3-4)]
TestCOMETRIQ (n=214)Placebo (N=109)
All Grades (%)Grade 3-4 (%)All Grades (%)Grade 3-4 (%)
Chemistries
Increased AST863352
Increased ALT866412
Increased ALP523353
Hypocalcemia5212273
Hypoalbuminemia432160
Hypophosphatemia283101
Hyperbilirubinemia252145
Hypomagnesemia19140
Hypokalemia18493
Hyponatremia10250
Hematologic
Lymphopenia53165111
Neutropenia353152
Thrombocytopenia35043
ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase
","
Table 3 Per-Patient Incidence of Hypertension (Study 1)
Hypertension, JNCJoint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, JAMA 2003: 289:2560. Criteria applied were modified, as multiple readings were not available per timepoint, and therefore not averaged. StagePatients classified by highest category based on all recorded blood pressure readings beginning after the first dose through 30 days after last dose.COMETRIQ N=211Patients with at least two blood pressure measurements after the first dose(%)Placebo N=107(%)
Normal: Grade 0: Systolic < 120 mmHg and Diastolic < 80 mmHg415
Pre-hypertension: Systolic ≥ 120 mmHg or Diastolic ≥ 80 mmHg3454
Stage 1: Systolic ≥ 140 mmHg or Diastolic ≥ 90 mmHg4625
Stage 2: Systolic ≥ 160 mmHg or Diastolic ≥ 100 mmHg155
Malignant: Diastolic ≥ 120 mmHg00
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise patients to read the FDA-approved patient labeling ( Patient Information ). Perforations and fistulas : Advise patients that gastrointestinal disorders such as diarrhea, nausea, vomiting, and constipation may develop during COMETRIQ treatment and to seek immediate medical attention if they experience persistent or severe abdominal pain because cases of gastrointestinal perforation and fistula have been reported in patients taking COMETRIQ [see Warnings and Precautions (5.1) ] . Hemorrhage : Instruct patients to contact their healthcare provider to seek immediate medical attention for signs or symptoms of unusual severe bleeding or hemorrhage [see Warnings and Precautions (5.2) ] . Thromboembolic events : Venous and arterial thrombotic events have been reported. Advise patients to report signs or symptoms of an arterial thrombosis. Venous thromboembolic events including pulmonary embolus have been reported. Advise patients to contact their health care provider if new onset of dyspnea, chest pain, or localized limb edema occurs [see Warnings and Precautions (5.3) ] . Impaired wound healing : Advise patients that COMETRIQ may impair wound healing. Advise patients to inform their healthcare provider of any planned surgical procedure [see Warnings and Precautions (5.4) ] . Hypertension and hypertensive crisis : Inform patients of the signs and symptoms of hypertension. Advise patients to undergo routine blood pressure monitoring and to contact their health care provider if blood pressure is elevated or if they experience signs or symptoms of hypertension [see Warnings and Precautions (5.5) ] . Cardiac failure : Advise patients that COMETRIQ can cause cardiac failure. Advise patients to immediately contact their healthcare provider for signs and symptoms of cardiac failure [see Warnings and Precautions (5.6) ] . Osteonecrosis of the jaw : Advise patients regarding good oral hygiene practices. Advise patients to immediately contact their healthcare provider for signs or symptoms associated with osteonecrosis of the jaw [see Warnings and Precautions (5.7) ] . Diarrhea : Advise patients to notify their healthcare provider at the first signs of poorly formed or loose stool or an increased frequency of bowel movements [see Warnings and Precautions (5.8) ] . Palmar-plantar erythrodysesthesia : Advise patients to contact their healthcare provider for progressive or intolerable rash [see Warnings and Precautions (5.9) ] . Reversible posterior leukoencephalopathy syndrome : Advise patients to immediately contact their health care provider for new onset or worsening neurological function [see Warnings and Precautions (5.11) ] . Embryo-fetal toxicity : Advise females of reproductive potential of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.12) , Use in Specific Populations (8.1) ] . Advise patients of reproductive potential to use effective contraception during treatment with COMETRIQ and for at least 4 months after the final dose [see Use in Specific Populations (8.3) ] . Lactation : Advise women not to breastfeed during treatment with COMETRIQ and for 4 months following the last dose [see Use in Specific Populations (8.2) ] . Drug interactions : Advise patients to inform their healthcare provider of all prescription or nonprescription medications, vitamins or herbal products. Inform patients to avoid grapefruit, grapefruit juice, and St. John’s wort [see Drug Interactions (7.1) , (7.2) ] . Hypocalcemia : Advise patients that COMETRIQ can cause low calcium levels and that their serum calcium levels should be monitored regularly during treatment. Advise patients to immediately contact their healthcare provider for signs or symptoms of hypocalcemia [see Warnings and Precautions (5.13) ] . Important administration information Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. Instruct patients that COMETRIQ capsules should not be opened or crushed and to take COMETRIQ capsules with a full glass (at least 8 ounces) of water. Manufactured for Exelixis, Inc. Alameda, CA 94502"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended Dose: 140 mg orally, once daily. ( 2.1 ) Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. ( 2.1 ) Do NOT substitute COMETRIQ capsules with cabozantinib tablets. ( 2.1 ) Hepatic Impairment: The recommended starting dose of COMETRIQ is 80 mg in patients with mild or moderate hepatic impairment. ( 2.1 ) 2.1 Recommended Dosage Do NOT substitute COMETRIQ capsules with cabozantinib tablets. The recommended daily dose of COMETRIQ is 140 mg once daily without food until disease progression or unacceptable toxicity. Instruct patients not to eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. Swallow COMETRIQ capsules whole. Do not open COMETRIQ capsules. Do not take a missed dose within 12 hours of the next dose. Do not ingest foods (e.g., grapefruit, grapefruit juice) or nutritional supplements that are known to inhibit cytochrome P450 while taking COMETRIQ. 2.2 Dosage Modifications for Adverse Reactions Withhold COMETRIQ for NCI CTCAE Grade 4 hematologic adverse reactions, Grade 3 or greater non-hematologic adverse reactions, intolerable Grade 2 adverse reactions, or osteonecrosis of the jaw. Upon resolution/improvement of the adverse reaction (i.e., return to baseline or resolution to Grade 1), reduce the dose as follows: If previously receiving 140 mg daily dose, resume treatment at 100 mg daily If previously receiving 100 mg daily dose, resume treatment at 60 mg daily If previously receiving 60 mg daily dose, resume at 60 mg if tolerated, otherwise, discontinue COMETRIQ Permanently discontinue COMETRIQ for any of the following: development of gastrointestinal (GI) perforation or Grade 4 fistula severe hemorrhage acute myocardial infarction or arterial or venous thromboembolic events that require medical intervention nephrotic syndrome severe hypertension that cannot be controlled with anti-hypertensive therapy or Grade 4 hypertension reversible posterior leukoencephalopathy syndrome cardiac failure, depending on severity 2.3 Dosage Modifications for Coadministration with Strong CYP3A4 Inhibitors Reduce the daily COMETRIQ dose by 40 mg (for example, from 140 mg to 100 mg daily or from 100 mg to 60 mg daily). Resume the dose that was used prior to initiating the CYP3A4 inhibitor 2 to 3 days after discontinuation of the strong inhibitor [see Drug Interactions (7.1) , Clinical Pharmacology (12.3) ]. 2.4 Dosage Modifications for Coadministration with Strong CYP3A4 Inducers Increase the daily COMETRIQ dose by 40 mg (for example, from 140 mg to 180 mg daily or from 100 mg to 140 mg daily) as tolerated. Resume the dose that was used prior to initiating the CYP3A4 inducer 2 to 3 days after discontinuation of the strong inducer. The daily dose of COMETRIQ should not exceed 180 mg [see Drug Interactions (7.2) , Clinical Pharmacology (12.3) ]. 2.5 Dosage Modifications for Patients with Hepatic Impairment The recommended starting dose of COMETRIQ for patients with mild to moderate hepatic impairment is 80 mg [see Use in Specific Populations (8.6) , Clinical Pharmacology (12.3) ] ."],"spl_product_data_elements":["COMETRIQ cabozantinib COMETRIQ cabozantinib cabozantinib s-malate cabozantinib cellulose, microcrystalline croscarmellose sodium sodium starch glycolate type a potato silicon dioxide stearic acid gelatin ferric oxide red ferrosoferric oxide titanium dioxide shellac butyl alcohol isopropyl alcohol propylene glycol ammonia Swedish Orange XL184;80mg COMETRIQ cabozantinib cabozantinib s-malate cabozantinib cellulose, microcrystalline croscarmellose sodium sodium starch glycolate type a potato silicon dioxide stearic acid gelatin ferrosoferric oxide titanium dioxide shellac butyl alcohol isopropyl alcohol propylene glycol ammonia XL184;20mg COMETRIQ cabozantinib COMETRIQ cabozantinib cabozantinib s-malate cabozantinib cellulose, microcrystalline croscarmellose sodium sodium starch glycolate type a potato silicon dioxide stearic acid gelatin ferric oxide red ferrosoferric oxide titanium dioxide shellac butyl alcohol isopropyl alcohol propylene glycol ammonia Swedish Orange XL184;80mg COMETRIQ cabozantinib cabozantinib s-malate cabozantinib cellulose, microcrystalline croscarmellose sodium sodium starch glycolate type a potato silicon dioxide stearic acid gelatin ferrosoferric oxide titanium dioxide shellac butyl alcohol isopropyl alcohol propylene glycol ammonia XL184;20mg COMETRIQ cabozantinib cabozantinib s-malate cabozantinib cellulose, microcrystalline croscarmellose sodium sodium starch glycolate type a potato silicon dioxide stearic acid gelatin ferrosoferric oxide titanium dioxide shellac butyl alcohol isopropyl alcohol propylene glycol ammonia XL184;20mg"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Capsules: 20-mg gelatin capsules, grey with \"XL184 20mg\" printed in black on the body of the capsule. 80-mg gelatin capsules, Swedish orange with \"XL184 80mg\" printed in black on the body of the capsule. Capsules: 20 mg and 80 mg. ( 3 )"],"spl_patient_package_insert":["PATIENT INFORMATION COMETRIQ ® (Ko-me-trik) cabozantinib capsules What is COMETRIQ? COMETRIQ is a prescription medicine used to treat people with medullary thyroid cancer that has spread to other parts of the body. It is not known if COMETRIQ is safe and effective in children. Before you take COMETRIQ, tell your healthcare provider about all of your medical conditions including if you: have a recent history of coughing up blood or bleeding or any unusual bleeding have an open or healing wound have high blood pressure have heart problems have a low calcium level in your blood (hypocalcemia) plan to have any surgery, a dental procedure, or have had a recent surgery. You should stop taking COMETRIQ at least 3 weeks before planned surgery. See \"What are the possible side effects of COMETRIQ?\" have liver problems are pregnant or plan to become pregnant. COMETRIQ can harm your unborn baby. If you are able to become pregnant, your healthcare provider will check your pregnancy status before you start treatment with COMETRIQ. Females who are able to become pregnant should use effective birth control (contraception) during treatment and for 4 months after the final dose of COMETRIQ. Talk to your healthcare provider about birth control methods that may be right for you. If you become pregnant or think you are pregnant, tell your healthcare provider right away. are breastfeeding or plan to breastfeed. It is not known if COMETRIQ passes into your breast milk. Do not breastfeed during treatment and for 4 months after the final dose of COMETRIQ. Tell your healthcare provider about all the medicines you take, including prescription or over-the-counter medicines, vitamins, and herbal supplements. COMETRIQ and certain other medicines may affect each other causing side effects. How should I take COMETRIQ? Take COMETRIQ exactly as your healthcare provider tells you to take it. Do not take COMETRIQ with food. Do not eat for at least 2 hours before and at least 1 hour after taking COMETRIQ. Swallow COMETRIQ capsules whole with a full glass (at least 8 ounces) of water. Do not crush or open COMETRIQ capsules. If you miss a dose and your next dose is in less than 12 hours, take your next dose at the normal time. Do not make up the missed dose. What should I avoid while taking COMETRIQ? Do not drink grapefruit juice, eat grapefruit or take supplements that contain grapefruit or St. John's wort during treatment with COMETRIQ. What are the possible side effects of COMETRIQ? COMETRIQ may cause serious side effects, including: a tear in your stomach or intestinal wall (perforation) or an abnormal connection between 2 parts of your body (fistula) that may lead to death. Tell your healthcare provider right away if you get tenderness or pain in your stomach-area (abdomen) that is severe or that does not go away. bleeding (hemorrhage) . COMETRIQ can cause severe bleeding that may lead to death. Tell your healthcare provider right away if you get any signs of bleeding during treatment with COMETRIQ, including: coughing up blood or blood clots vomiting blood or if your vomit looks like coffee-grounds red or black (looks like tar) stools menstrual bleeding that is heavier than normal any unusual or heavy bleeding blood clots, stroke, heart attack, and chest pain. Get emergency help right away if you get: swelling or pain in your arms or legs shortness of breath feel lightheaded or faint sweating more than usual numbness or weakness of your face, arm or leg, especially on one side of your body sudden confusion, trouble speaking or understanding sudden trouble seeing in one or both eyes sudden trouble walking dizziness, loss of balance or coordination a sudden severe headache wound healing problems. Wound healing problems have happened in some people who take COMETRIQ. Tell your healthcare provider if you plan to have any surgery before or during treatment with COMETRIQ. You should stop taking COMETRIQ at least 3 weeks before planned surgery. Your healthcare provider should tell you when you may start taking COMETRIQ again after surgery. high blood pressure (hypertension). Hypertension is common with COMETRIQ and can be severe. Your healthcare provider will check your blood pressure before starting COMETRIQ and regularly during treatment with COMETRIQ. If needed, your healthcare provider may prescribe medicine to treat your high blood pressure. Tell your healthcare provider if you develop severe headaches, nose bleeds, tiredness or confusion, vision changes, chest pain, trouble breathing, irregular heartbeat, or blood in your urine. heart problems. COMETRIQ can cause heart failure. Your healthcare provider may check your heart function before and during treatment with COMETRIQ. Tell your healthcare provider right away if you get any of the following signs and symptoms: feeling like your heart is pounding, racing, or beating irregularly shortness of breath swelling of your ankles or feet feeling lightheaded tiredness severe jaw bone problems (osteonecrosis). Your healthcare provider should examine your mouth before you start and during treatment with COMETRIQ. Tell your dentist that you are taking COMETRIQ. It is important for you to practice good mouth care during treatment with COMETRIQ. Tell your healthcare provider right away if you develop any symptoms of jaw problems including: jaw pain, toothache, or sores on your gums. diarrhea. Diarrhea is common with COMETRIQ and can be severe. If needed, your healthcare provider may prescribe medicine to treat your diarrhea. Tell your healthcare provider right away, if you have frequent loose, watery bowel movements. a skin problem called hand-foot skin reaction. Hand-foot skin reactions are common with COMETRIQ and can be severe. Tell your healthcare provider right away if you have rashes, redness, pain, swelling, or blisters on the palms of your hands or soles of your feet. protein in your urine and possible kidney problems. Symptoms may include swelling in your hands, arms, legs, or feet. Reversible Posterior Leukoencephalopathy Syndrome (RPLS). A condition called reversible posterior leukoencephalopathy syndrome can happen during treatment with COMETRIQ. Tell your healthcare provider right away if you have headaches, seizures, confusion, changes in vision, or problems thinking. decreased calcium level in your blood (hypocalcemia). COMETRIQ can cause you to have a decreased amount of calcium in your blood. Your healthcare provider will do blood tests to check you for this problem and give you calcium if needed. Tell your healthcare provider right away if you get any of the following signs or symptoms: muscle stiffness or muscle spasms numbness or tingling in your fingers, toes, or around your mouth seizures sudden weight gain swelling of your arms, hands, legs, and ankles Your healthcare provider may change your dose, temporarily stop, or permanently stop treatment with COMETRIQ if you have certain side effects. The most common side effects of COMETRIQ include: diarrhea redness, swelling or pain in your mouth or throat, or mouth sores. Tell your healthcare provider if these symptoms prevent you from eating or drinking. weight loss decreased appetite nausea tiredness hair color turning lighter change in taste pain in your abdomen constipation The most common abnormal blood test results with COMETRIQ include: increased liver function blood tests decreased white blood cell counts increased levels of enzyme called alkaline phosphatase in the blood (test for liver or bone problems) decreased calcium and phosphate blood le decreased platelet counts increased bilirubin blood levels COMETRIQ may cause fertility problems in females and males, which may affect your ability to have children. Talk to your healthcare provider if you have concerns about fertility. These are not all the possible side effects of COMETRIQ Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store COMETRIQ? Store COMETRIQ at room temperature between 68°F to 77°F (20°C to 25°C). Keep COMETRIQ and all medicines out of the reach of children. General information about the safe and effective use of COMETRIQ. Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use COMETRIQ for a condition for which it was not prescribed. Do not give COMETRIQ to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about COMETRIQ that is written for health professionals. What are the ingredients in COMETRIQ? Active ingredient: cabozantinib Inactive ingredients: silicified microcrystalline cellulose, croscarmellose sodium, sodium starch glycolate, fumed silica, and stearic acid Capsule shells: Grey gelatin capsule shells contain black iron oxide and titanium dioxide. Swedish orange gelatin capsule shells contain red iron oxide, and titanium dioxide. The printing ink contains shellac glaze, black iron oxide, N-butyl alcohol, isopropyl alcohol, propylene glycol, and ammonium hydroxide. Manufactured for Exelixis, Inc. Alameda, CA 94502 For more information, go to www.cometriq.com or call 1-855-292-3935. This Patient Information has been approved by the U.S. Food and Drug Administration. Revised 10/2025 image of chemical structure of COMETRIQ image of progression-free survival"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) 8.1 Pregnancy Risk Summary Based on findings from animal studies and its mechanism of action, COMETRIQ can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 )] . There are no available data in pregnant women to inform the drug-associated risk. In animal developmental and reproductive toxicology studies administration of cabozantinib to pregnant rats and rabbits during organogenesis resulted in embryofetal lethality and structural anomalies at exposures that were below those occurring clinically at the recommended dose (see Data ) . Advise pregnant women or women of childbearing potential of the potential hazard to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In an embryo-fetal development study in pregnant rats, daily oral administration of cabozantinib throughout organogenesis caused increased embryo-fetal lethality compared to controls at a dose of 0.03 mg/kg (less than 1% of the human exposure by AUC at the 140 mg dose). Findings included delayed ossifications and skeletal variations at a dose of 0.01 mg/kg/day (approximately 0.03% of the human exposure by AUC at the 140 mg dose). In pregnant rabbits, daily oral administration of cabozantinib throughout organogenesis resulted in findings of visceral malformations and variations including reduced spleen size and missing lung lobe at 3 mg/kg (approximately 11% of the human exposure by AUC at the 140 mg dose). In a pre- and postnatal study in rats, cabozantinib was administered orally from gestation day 10 through postnatal day 20. Cabozantinib did not produce adverse maternal toxicity or affect pregnancy, parturition or lactation of female rats, and did not affect the survival, growth or postnatal development of the offspring at doses up to 0.3 mg/kg/day (approximately 0.02 times the recommended clinical dose of 140 mg based on body surface area). 8.2 Lactation Risk Summary There is no information regarding the presence of cabozantinib or its metabolites in human milk, or their effects on the breastfed infant, or milk production. Because of the potential for serious adverse reactions in a breastfed infant from COMETRIQ, advise a lactating woman not to breastfeed during treatment with COMETRIQ and for 4 months after the final dose. 8.3 Females and Males of Reproductive Potential Pregnancy Testing Verify the pregnancy status of females of reproductive potential prior to initiating COMETRIQ [see Use in Specific Populations (8.1) ] . Contraception COMETRIQ can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1) ] . Females Advise females of reproductive potential to use effective contraception during treatment with COMETRIQ and for 4 months after the final dose. Infertility Females and Males Based on findings in animals, COMETRIQ may impair fertility in females and males of reproductive potential [see Nonclinical Toxicology ( 13.1 )] . 8.4 Pediatric Use The safety and effectiveness of COMETRIQ in pediatric patients have not been studied. Juvenile Animal Toxicity Data Juvenile rats were administered cabozantinib daily at doses of 1 or 2 mg/kg/day from Postnatal Day 12 (comparable to less than 2 years in humans) through Postnatal Day 35 or 70. Mortalities occurred at doses equal and greater than 1 mg/kg/day (approximately 0.07 times the clinical dose of 140 mg/day based on body surface area). Hypoactivity was observed at both doses tested on Postnatal Day 22. Targets were generally similar to those seen in adult animals, occurred at both doses, and included the kidney (nephropathy, glomerulonephritis), reproductive organs, gastrointestinal tract (cystic dilatation and hyperplasia in Brunner’s gland and inflammation of duodenum; and epithelial hyperplasia of colon and cecum), bone marrow (hypocellularity and lymphoid depletion), and liver. Tooth abnormalities and whitening as well as effects on bones including reduced bone mineral content and density, physeal hypertrophy, and decreased cortical bone also occurred at all dose levels. Recovery was not assessed at the 2 mg/kg dose level (approximately 0.14 times the clinical dose of 140 mg based on body surface area) due to high levels of mortality. At the low dose level, effects on bone parameters were partially resolved but effects on the kidney and epididymis/testis persisted after treatment ceased. 8.5 Geriatric Use Clinical studies of COMETRIQ did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. 8.6 Hepatic Impairment Increased exposure to cabozantinib has been observed in patients with mild to moderate hepatic impairment. Reduce the starting dose of COMETRIQ in patients with mild (Child-Pugh score (C-P) A) or moderate (C-P B) hepatic impairment. COMETRIQ is not recommended for use in patients with severe hepatic impairment [see Dosage and Administration (2.5) , Clinical Pharmacology (12.3) ] . 8.7 Renal Impairment Dosage adjustment is not required in patients with mild or moderate renal impairment. There is no experience with COMETRIQ in patients with severe renal impairment [see Clinical Pharmacology ( 12.3 )] ."],"package_label_principal_display_panel":["Package Label - CARTON - 140 mg Daily Dose of COMETRIQ PRINCIPAL DISPLAY PANEL Cometriq ® (cabozantinib) capsules 140 mg Daily Dose Blister Cards Each 140 mg daily dose contains a combination of one Swedish orange 80 mg and three grey 20 mg capsules. Each capsule contains cabozantinib ( S )-malate equivalent to 80 mg or 20 mg of cabozantinib. EXELIXIS ® NDC 42388-011-14 Carton containing 4 blister cards: The blister cards in this carton are for patients prescribed a 140 mg daily dose. Rx Only carton - 140 mg daily dose of COMETRIQ","Package Label - CARTON - 100 mg Daily Dose of COMETRIQ PRINCIPAL DISPLAY PANEL Cometriq ® (cabozantinib) capsules 100 mg Daily Dose Blister Cards Each 100 mg daily dose contains a combination of one Swedish orange 80 mg and one grey 20 mg capsule. Each capsule contains cabozantinib ( S )-malate equivalent to 80 mg or 20 mg of cabozantinib. EXELIXIS ® NDC 42388-012-14 Carton containing 4 blister cards: The blister cards in this carton are for patients prescribed a 100 mg daily dose. Rx Only carton - 100 mg daily dose of COMETRIQ","Package Label - CARTON - 60 mg Daily Dose of COMETRIQ PRINCIPAL DISPLAY PANEL Cometriq ® (cabozantinib) capsules 60 mg Daily Dose Blister Cards Each 60 mg daily dose contains three grey 20 mg capsules. Each capsule contains cabozantinib ( S )-malate equivalent to 20 mg of cabozantinib. EXELIXIS ® NDC 42388-013-14 Carton containing 4 blister cards: The blister cards in this carton are for patients prescribed a 60 mg daily dose. Rx Only carton - 60 mg daily dose of COMETRIQ"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility The carcinogenic potential of cabozantinib has been evaluated in two species: rasH2 transgenic mice and Sprague-Dawley rats. In the 2-year rat carcinogenicity study, once daily oral administration of cabozantinib resulted in a statistically significant increase in the incidence of malignant/complex malignant pheochromocytoma in combination with benign pheochromocytoma or in benign pheochromocytoma alone in male rats at a dose of 1 mg/kg (approximately 0.6 times the human exposure by AUC at the recommended 140 mg dose). Cabozantinib was not carcinogenic in a 26-week carcinogenicity study in rasH2 transgenic mice at a slightly higher exposure than the intended human therapeutic exposure. Cabozantinib was not mutagenic in vitro in the bacterial reverse mutation (Ames) assay and was not clastogenic in both the in vitro cytogenetic assay using human lymphocytes or in the in vivo mouse micronucleus assay. Based on nonclinical findings, male and female fertility may be impaired by treatment with COMETRIQ. In a fertility study in which cabozantinib was administered to male and female rats at doses of 1, 2.5, and 5 mg/kg/day, male fertility was significantly compromised at doses equal to or greater than 2.5 mg/kg/day (approximately equal to the human exposure by AUC at the recommended dose), with a decrease in sperm counts and reproductive organ weights. In females, fertility was significantly reduced at doses equal to or greater than 1 mg/kg/day (approximately 50% of the human exposure by AUC at the 140 mg recommended dose) with a significant decrease in the number of live embryos and a significant increase in pre- and post-implantation losses. Observations of effects on reproductive tract tissues in general toxicology studies were supportive of effects noted in the dedicated fertility study and included hypospermia and absence of corpora lutea in male and female dogs in a 6-month repeat dose study at exposures equal to 6% and 3%, respectively, the human exposure by AUC at the recommended dose. In addition, female rats administered 5 mg/kg/day for 14 days (approximately equal to the human exposure by AUC at the 140 mg recommended dose) exhibited ovarian necrosis."]},"tags":[{"label":"Kinase Inhibitor","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Vascular endothelial growth factor receptor 2","category":"target"},{"label":"KDR","category":"gene"},{"label":"MET","category":"gene"},{"label":"AXL","category":"gene"},{"label":"L01EX07","category":"atc"},{"label":"Oral","category":"route"},{"label":"Capsule","category":"form"},{"label":"Tablet","category":"form"},{"label":"Active","category":"status"},{"label":"Liver cell carcinoma","category":"indication"},{"label":"Medullary thyroid carcinoma","category":"indication"},{"label":"Metastatic renal cell carcinoma","category":"indication"},{"label":"Renal cell carcinoma","category":"indication"},{"label":"Exelixis","category":"company"},{"label":"Approved 2010s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"llr":3578.896,"date":"","count":1084,"signal":"Palmar-plantar erythrodysaesthesia syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 1,084 times (LLR=3579)"},{"llr":2192.884,"date":"","count":1111,"signal":"Malignant neoplasm progression","source":"DrugCentral FAERS","actionTaken":"Reported 1,111 times (LLR=2193)"},{"llr":1165.893,"date":"","count":1684,"signal":"Diarrhoea","source":"DrugCentral FAERS","actionTaken":"Reported 1,684 times (LLR=1166)"},{"llr":1021.405,"date":"","count":524,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 524 times (LLR=1021)"},{"llr":824.607,"date":"","count":420,"signal":"Hypothyroidism","source":"DrugCentral FAERS","actionTaken":"Reported 420 times (LLR=825)"},{"llr":799.938,"date":"","count":863,"signal":"Decreased appetite","source":"DrugCentral FAERS","actionTaken":"Reported 863 times (LLR=800)"},{"llr":578.965,"date":"","count":737,"signal":"Hypertension","source":"DrugCentral FAERS","actionTaken":"Reported 737 times (LLR=579)"},{"llr":566.873,"date":"","count":231,"signal":"Taste disorder","source":"DrugCentral FAERS","actionTaken":"Reported 231 times (LLR=567)"},{"llr":502.782,"date":"","count":259,"signal":"Proteinuria","source":"DrugCentral FAERS","actionTaken":"Reported 259 times (LLR=503)"},{"llr":459.169,"date":"","count":444,"signal":"Stomatitis","source":"DrugCentral FAERS","actionTaken":"Reported 444 times (LLR=459)"},{"llr":385.093,"date":"","count":120,"signal":"Hair colour changes","source":"DrugCentral FAERS","actionTaken":"Reported 120 times (LLR=385)"},{"llr":368.78,"date":"","count":449,"signal":"Disease progression","source":"DrugCentral FAERS","actionTaken":"Reported 449 times (LLR=369)"},{"llr":330.948,"date":"","count":694,"signal":"Malaise","source":"DrugCentral FAERS","actionTaken":"Reported 694 times (LLR=331)"},{"llr":254.833,"date":"","count":208,"signal":"Dysphonia","source":"DrugCentral FAERS","actionTaken":"Reported 208 times (LLR=255)"},{"llr":252.099,"date":"","count":322,"signal":"Inappropriate schedule of product administration","source":"DrugCentral FAERS","actionTaken":"Reported 322 times (LLR=252)"}],"drugInteractions":[{"drug":"Strong CYP3A4 Inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin, voriconazole)","severity":"major","mechanism":"Inhibition of CYP3A4","management":"Avoid concomitant use or reduce the dosage of COMETRIQ if concomitant use cannot be avoided","clinicalEffect":"Increased single-dose plasma cabozantinib exposure by 38%"},{"drug":"Foods or Nutritional Supplements that Inhibit Cytochrome P450 (e.g., grapefruit, grapefruit juice)","severity":"major","mechanism":"Inhibition of CYP3A4","management":"Avoid ingestion while taking COMETRIQ","clinicalEffect":"Increased exposure to cabozantinib"},{"drug":"Strong CYP3A4 Inducers (e.g., phenytoin, carbamazepine, rifampin, rifabutin, rifapentine, phenobarbital, St. John’s Wort)","severity":"major","mechanism":"Induction of CYP3A4","management":"Avoid chronic co-administration or increase the dosage of COMETRIQ if concomitant use cannot be avoided","clinicalEffect":"Decreased single-dose plasma cabozantinib exposure by 77%"},{"drug":"MRP2 Inhibitors (e.g., abacavir, adefovir, cidofovir, furosemide, lamivudine, nevirapine, ritonavir, probenecid, saquinavir, tenofovir)","severity":"moderate","mechanism":"Inhibition of MRP2","management":"Monitor patients for increased toxicity","clinicalEffect":"Increased exposure to cabozantinib"}],"commonSideEffects":[{"effect":"diarrhea","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"stomatitis","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"palmar-plantar erythrodysesthesia (PPE)","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"decreased weight","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"decreased appetite","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"nausea","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"fatigue","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"oral pain","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"hair color changes","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"dysgeusia","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"hypertension","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"abdominal pain","drugRate":"≥ 25%","_validated":true,"placeboRate":""},{"effect":"constipation","drugRate":"≥ 25%","_validated":true,"placeboRate":""}],"specialPopulations":{"Pregnancy":"COMETRIQ can cause fetal harm when administered to pregnant woman. There are no available data in pregnant women to inform the drug-associated risk. In animal developmental and reproductive toxicology studies administration of cabozantinib to pregnant rats and rabbits during organogenesis resulted in embryofetal lethality and structural anomalies at exposures that were below those occurring clinically at the recommended dose. Advise pregnant women or women of childbearing potential of the potential hazard to fetus.","Geriatric use":"No overall differences in safety or effectiveness were observed between these patients and younger patients.","Paediatric use":"The safety and effectiveness of COMETRIQ in pediatric patients have not been studied."},"discontinuationRates":[{"trial":"Study 1","drugArm":"16%","placeboArm":"","commonReason":"the most frequent adverse reactions leading to permanent discontinuation of COMETRIQ were: hypocalcemia, increased lipase, PPE, diarrhea, fatigue, hypertension, nausea, pancreatitis, tracheal fistula formation and vomiting"}],"seriousAdverseEvents":[{"event":"fatal adverse reactions","detail":"resulted from hemorrhage, pneumonia, septicemia, fistulas, cardiac arrest, respiratory failure, and unspecified death","severity":"serious","incidence":"6%"},{"event":"increased levels of thyroid stimulating hormone (TSH)","detail":"observed in 57% of patients receiving COMETRIQ after the first dose compared to 19% of patients receiving placebo","severity":"serious","incidence":"57%"}]},"trials":[],"aliases":["cabozantinib"],"company":"Exelixis","patents":[{"source":"FDA Orange Book via DrugCentral","expires":"2033-07-09","territory":"US","patentNumber":"9724342"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-02-10","territory":"US","patentNumber":"11298349"},{"source":"FDA Orange Book via DrugCentral","expires":"2032-02-10","territory":"US","patentNumber":"9717720"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-07-18","territory":"US","patentNumber":"10034873"},{"source":"FDA Orange Book via DrugCentral","expires":"2031-07-18","territory":"US","patentNumber":"10039757"},{"source":"FDA Orange Book via DrugCentral","expires":"2030-10-08","territory":"US","patentNumber":"8877776"},{"source":"FDA Orange Book via DrugCentral","expires":"2030-01-15","territory":"US","patentNumber":"11091439"},{"source":"FDA Orange Book via DrugCentral","expires":"2030-01-15","territory":"US","patentNumber":"11091440"},{"source":"FDA Orange Book via DrugCentral","expires":"2030-01-15","territory":"US","patentNumber":"11098015"},{"source":"FDA Orange Book via DrugCentral","expires":"2026-08-14","territory":"US","patentNumber":"7579473"},{"source":"FDA Orange Book via DrugCentral","expires":"2024-09-24","territory":"US","patentNumber":"8497284"}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=Cabometyx","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:28:13.431623+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:28:13.431134+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:29:47.985294+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:28:19.991128+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:28:13.448800+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cabometyx","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:28:20.824830+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:28:10.992488+00:00"},"indications.approved":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:36.963650+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:28:10.992538+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Hepatocyte growth factor receptor inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:28:21.433583+00:00"},"safety.drugInteractions":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:29:31.028512+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2103868/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:28:21.318722+00:00"},"safety.commonSideEffects":{"url":"","method":"ai_extraction","source":"FDA Label + AI","aiModel":"featherless","rawText":"6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed elsewhere in the labeling: Perforations and Fistula [see Warnings and Precautions (5.1) ] Hemorrhage [see Warnings and Precautions (5.2) ] Thromboembolic Events [see Warnings and Precautions (5.3) ] Impaired Wound Healing [see Warnings and Precautions (5.4) ] Hypertension and Hypertensive Crisis [see Warnings and Precautions (5.5) ] Cardiac Failure [see Warnings and Precautions (5.6) ] Osteonecrosis of the J","confidence":0.95,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:28:58.795991+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA203756","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:28:10.992543+00:00"}},"allNames":"cometriq","offLabel":[],"synonyms":["cabozantinib malate","cabozantinib (S)-malate","cabozantinib","cometriq","XL184","cabozantinib S-malate","cabometyx"],"timeline":[{"date":"2012-11-29","type":"positive","source":"DrugCentral","milestone":"FDA approval (Exelixis)"},{"date":"2014-03-21","type":"positive","source":"DrugCentral","milestone":"EMA approval (TMC Pharma Services Ltd)"},{"date":"2020-03-25","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Takeda Pharmaceutical Company Limited)"}],"aiSummary":"Cabometyx, marketed by Exelixis, is a targeted therapy for progressive, metastatic medullary thyroid cancer, with a key composition patent expiring in 2028. Its mechanism of blocking the VEGFR2 pathway to inhibit tumor growth and angiogenesis provides a strong therapeutic profile, distinguishing it from other same-class competitors like sunitinib and sorafenib. The primary risk lies in the increasing availability of generics for off-patent competitors, which could erode market share and revenue.","brandName":"Cometriq","ecosystem":[{"indication":"Liver cell carcinoma","otherDrugs":[{"name":"atezolizumab","slug":"atezolizumab","company":"Genentech Inc"},{"name":"bevacizumab","slug":"bevacizumab","company":"Genentech"},{"name":"durvalumab","slug":"durvalumab","company":"Astrazeneca Uk Ltd"},{"name":"lenvatinib","slug":"lenvatinib","company":"Eisai Inc"}],"globalPrevalence":null},{"indication":"Medullary thyroid carcinoma","otherDrugs":[{"name":"pralsetinib","slug":"pralsetinib","company":"Blueprint Medicines"},{"name":"selpercatinib","slug":"selpercatinib","company":"Loxo Oncology Inc"},{"name":"vandetanib","slug":"vandetanib","company":"Ipr Pharms Inc"}],"globalPrevalence":null},{"indication":"Metastatic renal cell carcinoma","otherDrugs":[{"name":"aldesleukin","slug":"aldesleukin","company":"Chiron"},{"name":"bevacizumab","slug":"bevacizumab","company":"Genentech"},{"name":"nivolumab","slug":"nivolumab","company":"Bristol Myers Squibb"},{"name":"pembrolizumab","slug":"pembrolizumab","company":"Merck Sharp Dohme"}],"globalPrevalence":3360000},{"indication":"Renal cell carcinoma","otherDrugs":[{"name":"avelumab","slug":"avelumab","company":"Emd Serono Inc"},{"name":"axitinib","slug":"axitinib","company":"Pfizer"},{"name":"everolimus","slug":"everolimus","company":"Novartis"},{"name":"ipilimumab","slug":"ipilimumab","company":"Bristol Myers Squibb"}],"globalPrevalence":3360000}],"mechanism":{"target":"Vascular endothelial growth factor receptor 2","novelty":"Follow-on","targets":[{"gene":"KDR","source":"DrugCentral","target":"Vascular endothelial growth factor receptor 2","protein":"Vascular endothelial growth factor receptor 2"},{"gene":"MET","source":"DrugCentral","target":"Hepatocyte growth factor receptor","protein":"Hepatocyte growth factor receptor"},{"gene":"AXL","source":"DrugCentral","target":"Tyrosine-protein kinase receptor UFO","protein":"Tyrosine-protein kinase receptor UFO"},{"gene":"KIT","source":"DrugCentral","target":"Mast/stem cell growth factor receptor Kit","protein":"Mast/stem cell growth factor receptor Kit"},{"gene":"RET","source":"DrugCentral","target":"Proto-oncogene tyrosine-protein kinase receptor Ret","protein":"Proto-oncogene tyrosine-protein kinase receptor Ret"},{"gene":"FLT4","source":"DrugCentral","target":"Vascular endothelial growth factor receptor 3","protein":"Vascular endothelial growth factor receptor 3"},{"gene":"FGFR1","source":"DrugCentral","target":"Fibroblast growth factor receptor 1","protein":"Fibroblast growth factor receptor 1"},{"gene":"FLT3","source":"DrugCentral","target":"Receptor-type tyrosine-protein kinase FLT3","protein":"Receptor-type tyrosine-protein kinase FLT3"},{"gene":"FLT1","source":"DrugCentral","target":"Vascular endothelial growth factor receptor 1","protein":"Vascular endothelial growth factor receptor 1"},{"gene":"TEK","source":"DrugCentral","target":"Angiopoietin-1 receptor","protein":"Angiopoietin-1 receptor"}],"moaClass":"Protein Kinase Inhibitors","modality":"Small Molecule","drugClass":"Kinase Inhibitor","explanation":"In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of RET, MET, VEGFR-1, -2 and -3, KIT, TRKB, FLT-3, AXL, ROS1, TYRO3, MER, and TIE-2. These receptor tyrosine kinases are involved in both normal cellular function and pathologic processes such as oncogenesis, metastasis, tumor angiogenesis, drug resistance, and maintenance of the tumor microenvironment.","oneSentence":"Cometriq blocks the VEGFR2 pathway to prevent tumor growth and angiogenesis.","technicalDetail":"Cometriq is a selective inhibitor of VEGFR2, a receptor tyrosine kinase involved in angiogenesis and tumor growth. By binding to the ATP-binding site of VEGFR2, Cometriq prevents the activation of downstream signaling pathways, ultimately leading to the inhibition of tumor growth and angiogenesis."},"commercial":{"launchDate":"2012","revenueYear":2024,"_launchSource":"DrugCentral (FDA 2012-11-29, EXELIXIS)","annualRevenue":2200,"revenueSource":"Verified: Exelixis 10-K","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4715","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=Cabometyx","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Cabometyx","fields":["publications"],"source":"PubMed/NCBI"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T02:41:06.222299","_validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T00:29:47.986048+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"sunitinib","drugSlug":"sunitinib","fdaApproval":"2006-01-26","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"sorafenib","drugSlug":"sorafenib","fdaApproval":"2005-12-20","patentExpiry":"Sep 10, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pazopanib","drugSlug":"pazopanib","fdaApproval":"2009-10-19","genericCount":6,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"vandetanib","drugSlug":"vandetanib","fdaApproval":"2011-04-06","patentExpiry":"Aug 8, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"regorafenib","drugSlug":"regorafenib","fdaApproval":"2012-09-27","patentExpiry":"Jun 2, 2030","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"lenvatinib","drugSlug":"lenvatinib","fdaApproval":"2015-02-13","patentExpiry":"Sep 3, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"nintedanib","drugSlug":"nintedanib","fdaApproval":"2014-10-15","patentExpiry":"Jun 7, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"midostaurin","drugSlug":"midostaurin","fdaApproval":"2017-04-28","patentExpiry":"Oct 9, 2028","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"quizartinib","drugSlug":"quizartinib","fdaApproval":"2023-07-20","patentExpiry":"Sep 30, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"larotrectinib","drugSlug":"larotrectinib","fdaApproval":"2018-11-26","patentExpiry":"Oct 21, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"gilteritinib","drugSlug":"gilteritinib","fdaApproval":"2018-11-28","patentExpiry":"Nov 28, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"entrectinib","drugSlug":"entrectinib","fdaApproval":"2019-08-15","patentExpiry":"May 22, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pexidartinib","drugSlug":"pexidartinib","fdaApproval":"2019-08-02","patentExpiry":"Nov 21, 2027","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"capmatinib","drugSlug":"capmatinib","fdaApproval":"2020-05-06","patentExpiry":"Nov 19, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"avapritinib","drugSlug":"avapritinib","fdaApproval":"2020-01-09","patentExpiry":"Oct 15, 2034","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ripretinib","drugSlug":"ripretinib","fdaApproval":"2020-05-15","patentExpiry":"Oct 6, 2042","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"tepotinib","drugSlug":"tepotinib","fdaApproval":"2021-02-03","patentExpiry":"Oct 30, 2029","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"selpercatinib","drugSlug":"selpercatinib","fdaApproval":"2020-05-08","patentExpiry":"Oct 10, 2038","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"pralsetinib","drugSlug":"pralsetinib","fdaApproval":"2020-09-04","patentExpiry":"Nov 1, 2036","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"umbralisib","drugSlug":"umbralisib","fdaApproval":"2021-02-05","patentExpiry":"May 26, 2035","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"cabometyx","indications":{"approved":[{"id":"cabometyx-progressive,-metastatic-medull","name":"Progressive, Metastatic Medullary Thyroid Cancer","dosing":null,"approvals":[],"diseaseId":"","eligibility":"Patients with progressive, metastatic medullary thyroid cancer (MTC)","pivotalTrial":null,"restrictions":[],"patientPopulation":"Patients with progressive, metastatic medullary thyroid cancer (MTC)","diagnosticRequired":null,"brandNameForIndication":"Cometriq"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"sunitinib","brandName":"sunitinib","genericName":"sunitinib","approvalYear":"2006","relationship":"same-class"},{"drugId":"sorafenib","brandName":"sorafenib","genericName":"sorafenib","approvalYear":"2005","relationship":"same-class"},{"drugId":"pazopanib","brandName":"pazopanib","genericName":"pazopanib","approvalYear":"2009","relationship":"same-class"},{"drugId":"vandetanib","brandName":"vandetanib","genericName":"vandetanib","approvalYear":"2011","relationship":"same-class"},{"drugId":"regorafenib","brandName":"regorafenib","genericName":"regorafenib","approvalYear":"2012","relationship":"same-class"},{"drugId":"lenvatinib","brandName":"lenvatinib","genericName":"lenvatinib","approvalYear":"2015","relationship":"same-class"},{"drugId":"nintedanib","brandName":"nintedanib","genericName":"nintedanib","approvalYear":"2014","relationship":"same-class"},{"drugId":"midostaurin","brandName":"midostaurin","genericName":"midostaurin","approvalYear":"2017","relationship":"same-class"},{"drugId":"quizartinib","brandName":"quizartinib","genericName":"quizartinib","approvalYear":"2023","relationship":"same-class"},{"drugId":"larotrectinib","brandName":"larotrectinib","genericName":"larotrectinib","approvalYear":"2018","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT02243605","phase":"PHASE2","title":"Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-19","conditions":["Metastatic Ewing Sarcoma","Metastatic Osteosarcoma","Recurrent Ewing Sarcoma","Recurrent Osteosarcoma","Stage III Osteosarcoma AJCC v7","Stage IV Osteosarcoma AJCC v7","Stage IVA Osteosarcoma AJCC v7","Stage IVB Osteosarcoma AJCC v7","Unresectable Ewing Sarcoma","Unresectable Osteosarcoma"],"enrollment":90,"completionDate":"2026-07-11"},{"nctId":"NCT05773274","phase":"PHASE2","title":"Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-01-12","conditions":["Metastatic Digestive System Neuroendocrine Tumor G1","Metastatic Digestive System Neuroendocrine Tumor G2","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Digestive System Neuroendocrine Tumor G2"],"enrollment":100,"completionDate":"2026-04-30"},{"nctId":"NCT02496208","phase":"PHASE1","title":"Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-07-22","conditions":["Bladder Small Cell Neuroendocrine Carcinoma","Bladder Squamous Cell Carcinoma","Bladder Urothelial Carcinoma","Clear Cell Renal Cell Carcinoma","Invasive Bladder Plasmacytoid Urothelial Carcinoma","Invasive Bladder Sarcomatoid Urothelial Carcinoma","Invasive Sarcomatoid Urothelial Carcinoma","Kidney Medullary Carcinoma","Malignant Genitourinary System Neoplasm","Malignant Solid Neoplasm","Penile Carcinoma","Penile Squamous Cell Carcinoma","Renal Cell Carcinoma","Renal Pelvis Urothelial Carcinoma","Sarcomatoid Renal Cell Carcinoma","Stage III Bladder Cancer AJCC v8","Stage III Penile Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage III Renal Pelvis and Ureter Cancer AJCC v8","Stage III Renal Pelvis Cancer AJCC v8","Stage III Ureter Cancer AJCC v8","Stage III Urethral Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8","Stage IV Penile Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IV Renal Pelvis and Ureter Cancer AJCC v8","Stage IV Ureter Cancer AJCC v8","Stage IV Urethral Cancer AJCC v8","Ureter Urothelial Carcinoma","Urethral Urothelial Carcinoma"],"enrollment":152,"completionDate":"2026-09-30"},{"nctId":"NCT05136196","phase":"PHASE2","title":"BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-12-06","conditions":["Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8","Locally Recurrent Head and Neck Squamous Cell Carcinoma","Locally Recurrent Hypopharyngeal Squamous Cell Carcinoma","Locally Recurrent Laryngeal Squamous Cell Carcinoma","Locally Recurrent Oral Cavity Squamous Cell Carcinoma","Locally Recurrent Oropharyngeal Squamous Cell Carcinoma","Metastatic Head and Neck Squamous Cell Carcinoma","Metastatic Hypopharyngeal Squamous Cell Carcinoma","Metastatic Laryngeal Squamous Cell Carcinoma","Metastatic Melanoma","Metastatic Oral Cavity Squamous Cell Carcinoma","Metastatic Oropharyngeal Squamous Cell Carcinoma","Recurrent Melanoma","Stage III Hypopharyngeal Carcinoma AJCC v8","Stage III Laryngeal Cancer AJCC v8","Stage III Lip and Oral Cavity Cancer AJCC v8","Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Stage IV Hypopharyngeal Carcinoma AJCC v8","Stage IV Laryngeal Cancer AJCC v8","Stage IV Lip and Oral Cavity Cancer AJCC v8","Stage IV Oropharyngeal (p16-Negative) Carcinoma AJCC v8","Unresectable Melanoma"],"enrollment":150,"completionDate":"2027-01-01"},{"nctId":"NCT03375320","phase":"PHASE3","title":"Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-10-26","conditions":["Functioning Pancreatic Neuroendocrine Tumor","Intermediate Grade Lung Neuroendocrine Neoplasm","Locally Advanced Digestive System Neuroendocrine Neoplasm","Locally Advanced Digestive System Neuroendocrine Tumor G1","Locally Advanced Lung Neuroendocrine Neoplasm","Locally Advanced Pancreatic Neuroendocrine Tumor","Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm","Low Grade Lung Neuroendocrine Neoplasm","Lung Neuroendocrine Tumor","Lung Neuroendocrine Tumor G2","Metastatic Digestive System Neuroendocrine Neoplasm","Metastatic Digestive System Neuroendocrine Tumor G1","Metastatic Lung Neuroendocrine Neoplasm","Metastatic Lung Neuroendocrine Tumor","Metastatic Pancreatic Neuroendocrine Neoplasm","Metastatic Pancreatic Neuroendocrine Tumor","Metastatic Thymus Neuroendocrine Neoplasm","Neuroendocrine Neoplasm","Neuroendocrine Tumor","Neuroendocrine Tumor G2","Non-Functioning Pancreatic Neuroendocrine Tumor","Pancreatic Serotonin-Producing Neuroendocrine Tumor","Thymus Neuroendocrine Tumor","Unresectable Digestive System Neuroendocrine Neoplasm","Unresectable Digestive System Neuroendocrine Tumor G1","Unresectable Lung Neuroendocrine Neoplasm","Unresectable Pancreatic Neuroendocrine Neoplasm","Unresectable Thymus Neuroendocrine Neoplasm"],"enrollment":298,"completionDate":"2026-08-19"},{"nctId":"NCT05691478","phase":"PHASE2,PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":["High Grade Osteosarcoma","Localized Osteosarcoma","Metastatic Osteosarcoma","Secondary Osteosarcoma"],"enrollment":1122,"completionDate":"2030-03-20"},{"nctId":"NCT06811116","phase":"PHASE1,PHASE2","title":"Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2025-11-17","conditions":["Advanced Hepatocellular Carcinoma","Metastatic Hepatocellular Carcinoma","Stage III Hepatocellular Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8"],"enrollment":92,"completionDate":"2027-08-31"},{"nctId":"NCT03793166","phase":"PHASE3","title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-06-07","conditions":["Clear Cell Renal Cell Carcinoma","Metastatic Malignant Neoplasm in the Bone","Metastatic Malignant Neoplasm in the Lymph Nodes","Metastatic Malignant Neoplasm in the Soft Tissue","Metastatic Malignant Neoplasm in the Viscera","Rhabdoid Tumor of the Kidney","Sarcomatoid Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":1175,"completionDate":"2028-01-25"},{"nctId":"NCT05904080","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-02-19","conditions":["Metastatic Nasopharyngeal Carcinoma","Recurrent Nasopharyngeal Carcinoma","Stage IV Nasopharyngeal Carcinoma AJCC v8"],"enrollment":50,"completionDate":"2028-06-16"},{"nctId":"NCT04071223","phase":"PHASE2","title":"Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-29","conditions":["Advanced Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Clear Cell Renal Cell Carcinoma","Collecting Duct Carcinoma","Kidney Medullary Carcinoma","Metastatic Malignant Neoplasm in the Bone","Papillary Renal Cell Carcinoma","Stage IV Renal Cell Cancer AJCC v8","Unclassified Renal Cell Carcinoma"],"enrollment":134,"completionDate":"2026-10-01"},{"nctId":"NCT03866382","phase":"PHASE2","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-05-13","conditions":["Bladder Adenocarcinoma","Bladder Clear Cell Adenocarcinoma","Bladder Mixed Adenocarcinoma","Bladder Neuroendocrine Carcinoma","Bladder Small Cell Neuroendocrine Carcinoma","Bladder Squamous Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Collecting Duct Carcinoma","Invasive Bladder Giant Cell Urothelial Carcinoma","Invasive Bladder Lymphoepithelioma-Like Carcinoma","Invasive Bladder Nested Urothelial Carcinoma","Invasive Bladder Plasmacytoid Urothelial Carcinoma","Invasive Bladder Sarcomatoid Urothelial Carcinoma","Invasive Bladder Urothelial Carcinoma","Kidney Medullary Carcinoma","Large Cell Neuroendocrine Carcinoma","Malignant Testicular Leydig Cell Tumor","Malignant Testicular Sertoli Cell Tumor","Metastatic Bladder Carcinoma","Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma","Metastatic Bladder Giant Cell Urothelial Carcinoma","Metastatic Bladder Large Cell Neuroendocrine Carcinoma","Metastatic Bladder Lipid-Rich Urothelial Carcinoma","Metastatic Bladder Micropapillary Urothelial Carcinoma","Metastatic Bladder Plasmacytoid Urothelial Carcinoma","Metastatic Bladder Sarcomatoid Urothelial Carcinoma","Metastatic Bladder Small Cell Neuroendocrine Carcinoma","Metastatic Bladder Squamous Cell Carcinoma","Metastatic Chromophobe Renal Cell Carcinoma","Metastatic Kidney Medullary Carcinoma","Metastatic Malignant Genitourinary System Neoplasm","Metastatic Papillary Renal Cell Carcinoma","Metastatic Penile Carcinoma","Metastatic Prostate Small Cell Neuroendocrine Carcinoma","Metastatic Sarcomatoid Renal Cell Carcinoma","Metastatic Urethral Carcinoma","Papillary Renal Cell Carcinoma","Sarcomatoid Renal Cell Carcinoma","Stage IV Bladder Cancer AJCC v8","Stage IV Penile Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IV Urethral Cancer AJCC v8","Stage IVB Prostate Cancer AJCC v8","Urachal Adenocarcinoma","Urethral Clear Cell Adenocarcinoma"],"enrollment":314,"completionDate":"2027-02-28"},{"nctId":"NCT05111574","phase":"PHASE2","title":"Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-08-11","conditions":["Anal Melanoma","Bladder Melanoma","Cervical Melanoma","Esophageal Melanoma","Gallbladder Melanoma","Head and Neck Mucosal Melanoma","Mucosal Melanoma","Nasopharyngeal Mucosal Melanoma","Oral Cavity Mucosal Melanoma","Penile Mucosal Melanoma","Rectal Melanoma","Recurrent Mucosal Melanoma","Sinonasal Mucosal Melanoma","Urethral Melanoma","Urinary System Mucosal Melanoma","Vaginal Melanoma","Vulvar Melanoma"],"enrollment":101,"completionDate":"2026-06-01"},{"nctId":"NCT05411081","phase":"PHASE2","title":"Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, PAPMET2 Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-24","conditions":["Metastatic Papillary Renal Cell Carcinoma","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":200,"completionDate":"2027-07-01"},{"nctId":"NCT05092958","phase":"PHASE3","title":"Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-06-03","conditions":["Advanced Bladder Urothelial Carcinoma","Advanced Renal Pelvis Urothelial Carcinoma","Advanced Ureter Urothelial Carcinoma","Advanced Urethral Urothelial Carcinoma","Metastatic Bladder Urothelial Carcinoma","Metastatic Renal Pelvis Urothelial Carcinoma","Metastatic Ureter Urothelial Carcinoma","Metastatic Urethral Urothelial Carcinoma","Stage III Bladder Cancer AJCC v8","Stage III Renal Pelvis and Ureter Cancer AJCC v8","Stage III Renal Pelvis Cancer AJCC v8","Stage III Ureter Cancer AJCC v8","Stage III Urethral Cancer AJCC v8","Stage IV Bladder Cancer AJCC v8","Stage IV Renal Pelvis and Ureter Cancer AJCC v8","Stage IV Renal Pelvis Cancer AJCC v8","Stage IV Ureter Cancer AJCC v8","Stage IV Urethral Cancer AJCC v8"],"enrollment":654,"completionDate":"2026-06-15"},{"nctId":"NCT07227402","phase":"PHASE3","title":"A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-11-26","conditions":["Renal Cell Carcinoma"],"enrollment":904,"completionDate":"2032-02-27"},{"nctId":"NCT03914300","phase":"PHASE2","title":"Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-02-10","conditions":["Differentiated Thyroid Gland Carcinoma","Follicular Variant Thyroid Gland Papillary Carcinoma","Poorly Differentiated Thyroid Gland Carcinoma","Refractory Differentiated Thyroid Gland Carcinoma","Refractory Thyroid Gland Carcinoma","Tall Cell Variant Thyroid Gland Papillary Carcinoma","Thyroid Gland Follicular Carcinoma","Thyroid Gland Oncocytic Carcinoma","Thyroid Gland Papillary Carcinoma"],"enrollment":11,"completionDate":"2026-12-17"},{"nctId":"NCT04310007","phase":"PHASE2","title":"Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-07-13","conditions":["Metastatic Lung Non-Squamous Non-Small Cell Carcinoma","Recurrent Lung Non-Squamous Non-Small Cell Carcinoma","Stage IV Lung Cancer AJCC v8"],"enrollment":117,"completionDate":"2026-12-31"},{"nctId":"NCT06900595","phase":"PHASE2","title":"Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-02-22","conditions":["Locally Advanced Adrenal Cortical Carcinoma","Metastatic Adrenal Cortical Carcinoma","Recurrent Adrenal Cortical Carcinoma","Stage III Adrenal Cortical Carcinoma AJCC v8","Stage IV Adrenal Cortical Carcinoma AJCC v8","Unresectable Adrenal Cortical Carcinoma"],"enrollment":48,"completionDate":"2029-06-02"},{"nctId":"NCT02867592","phase":"PHASE2","title":"Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-05-18","conditions":["Adrenal Cortical Carcinoma","Alveolar Soft Part Sarcoma","Central Nervous System Neoplasm","Childhood Clear Cell Sarcoma of Soft Tissue","Clear Cell Sarcoma of Soft Tissue","Ewing Sarcoma","Hepatoblastoma","Hepatocellular Carcinoma","Osteosarcoma","Recurrent Adrenal Cortical Carcinoma","Recurrent Alveolar Soft Part Sarcoma","Recurrent Clear Cell Sarcoma of Soft Tissue","Recurrent Ewing Sarcoma","Recurrent Hepatoblastoma","Recurrent Hepatocellular Carcinoma","Recurrent Kidney Wilms Tumor","Recurrent Malignant Solid Neoplasm","Recurrent Osteosarcoma","Recurrent Primary Malignant Central Nervous System Neoplasm","Recurrent Renal Cell Carcinoma","Recurrent Rhabdomyosarcoma","Recurrent Soft Tissue Sarcoma","Recurrent Thyroid Gland Medullary Carcinoma","Refractory Adrenal Cortical Carcinoma","Refractory Alveolar Soft Part Sarcoma","Refractory Clear Cell Sarcoma of Soft Tissue","Refractory Ewing Sarcoma","Refractory Hepatoblastoma","Refractory Hepatocellular Carcinoma","Refractory Malignant Solid Neoplasm","Refractory Osteosarcoma","Refractory Primary Central Nervous System Neoplasm","Refractory Primary Malignant Central Nervous System Neoplasm","Refractory Renal Cell Carcinoma","Refractory Rhabdomyosarcoma","Refractory Soft Tissue Sarcoma","Refractory Thyroid Gland Medullary Carcinoma","Refractory Wilms Tumor","Renal Cell Carcinoma","Rhabdomyosarcoma","Soft Tissue Sarcoma","Solid Neoplasm","Thyroid Gland Medullary Carcinoma","Wilms Tumor"],"enrollment":109,"completionDate":"2026-06-27"},{"nctId":"NCT04079712","phase":"PHASE2","title":"Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-06","conditions":["Metastatic Large Cell Neuroendocrine Carcinoma","Metastatic Neuroendocrine Carcinoma","Metastatic Neuroendocrine Neoplasm","Metastatic Small Cell Neuroendocrine Carcinoma"],"enrollment":17,"completionDate":"2026-08-19"},{"nctId":"NCT03899155","phase":"PHASE2","title":"Pan Tumor Rollover Study","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2019-08-09","conditions":["Cancer"],"enrollment":1500,"completionDate":"2029-08-25"},{"nctId":"NCT06475989","phase":"PHASE3","title":"Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer","status":"RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2024-08-22","conditions":["Refractory Differentiated Thyroid Gland Carcinoma"],"enrollment":264,"completionDate":"2030-09-30"},{"nctId":"NCT04514484","phase":"PHASE1","title":"Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-11-22","conditions":["Advanced Differentiated Thyroid Gland Carcinoma","Advanced Head and Neck Carcinoma","Advanced Hepatocellular Carcinoma","Advanced Kaposi Sarcoma","Advanced Lung Non-Small Cell Carcinoma","Advanced Lung Small Cell Carcinoma","Advanced Malignant Solid Neoplasm","Advanced Melanoma","Advanced Ovarian Carcinoma","Advanced Prostate Carcinoma","Advanced Renal Cell Carcinoma","Advanced Thyroid Gland Medullary Carcinoma","Advanced Triple-Negative Breast Carcinoma","Advanced Urothelial Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Castration-Resistant Prostate Carcinoma","Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","HIV Infection","Metastatic Differentiated Thyroid Gland Carcinoma","Metastatic Head and Neck Carcinoma","Metastatic Hepatocellular Carcinoma","Metastatic Kaposi Sarcoma","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Lung Small Cell Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Ovarian Carcinoma","Metastatic Prostate Carcinoma","Metastatic Renal Cell Carcinoma","Metastatic Thyroid Gland Medullary Carcinoma","Metastatic Triple-Negative Breast Carcinoma","Metastatic Urothelial Carcinoma","Recurrent Differentiated Thyroid Gland Carcinoma","Recurrent Head and Neck Carcinoma","Recurrent Hepatocellular Carcinoma","Recurrent Kaposi Sarcoma","Recurrent Lung Non-Small Cell Carcinoma","Recurrent Lung Small Cell Carcinoma","Recurrent Malignant Solid Neoplasm","Recurrent Melanoma","Recurrent Ovarian Carcinoma","Recurrent Prostate Carcinoma","Recurrent Renal Cell Carcinoma","Recurrent Thyroid Gland Medullary Carcinoma","Recurrent Triple-Negative Breast Carcinoma","Recurrent Urothelial Carcinoma","Refractory Differentiated Thyroid Gland Carcinoma","Stage III Differentiated Thyroid Gland Carcinoma AJCC v8","Stage III Hepatocellular Carcinoma AJCC v8","Stage III Lung Cancer AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Prostate Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage III Thyroid Gland Medullary Carcinoma AJCC v8","Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Prostate Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IV Thyroid Gland Medullary Carcinoma AJCC v8"],"enrollment":8,"completionDate":"2027-02-06"},{"nctId":"NCT05700461","phase":"PHASE1","title":"Drug Screening Using Novel IMD in Renal Cell Carcinoma","status":"ENROLLING_BY_INVITATION","sponsor":"Oliver Jonas","startDate":"2024-12-01","conditions":["Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Kidney Cancer"],"enrollment":20,"completionDate":"2029-08-31"},{"nctId":"NCT04211337","phase":"PHASE3","title":"A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2020-02-11","conditions":["Medullary Thyroid Cancer"],"enrollment":291,"completionDate":"2027-11"},{"nctId":"NCT04338269","phase":"PHASE3","title":"A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2020-07-28","conditions":["Carcinoma, Renal Cell"],"enrollment":522,"completionDate":"2025-03-24"},{"nctId":"NCT07405164","phase":"PHASE3","title":"Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-03-23","conditions":["Von Hippel-Lindau Disease","Carcinoma, Renal Cell"],"enrollment":450,"completionDate":"2034-01-14"},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":["Metastatic Ewing Sarcoma"],"enrollment":15,"completionDate":"2030-10"},{"nctId":"NCT03945773","phase":"PHASE2","title":"Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors","status":"COMPLETED","sponsor":"Ipsen","startDate":"2020-01-08","conditions":["Locally Advanced or Metastatic Renal Cell Carcinoma"],"enrollment":127,"completionDate":"2026-02-12"},{"nctId":"NCT07011719","phase":"PHASE3","title":"Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma","status":"RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2025-09-08","conditions":["Metastatic Clear Cell Renal Cell Carcinoma","Advanced Clear Cell Renal Cell Carcinoma"],"enrollment":720,"completionDate":"2030-12"},{"nctId":"NCT06502171","phase":"PHASE1","title":"Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas","status":"NOT_YET_RECRUITING","sponsor":"Girish Dhall, MD","startDate":"2026-08-01","conditions":["Neurofibromatosis 1","Plexiform Neurofibroma"],"enrollment":30,"completionDate":"2034-08-01"},{"nctId":"NCT05019703","phase":"PHASE2","title":"Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-04-25","conditions":["Locally Advanced Osteosarcoma","Metastatic Osteosarcoma","Recurrent Osteosarcoma","Refractory Osteosarcoma","Unresectable Osteosarcoma"],"enrollment":40,"completionDate":"2027-12-31"},{"nctId":"NCT05425004","phase":"PHASE2","title":"Cabozantinib for Patients With Recurrent or Progressive Meningioma","status":"RECRUITING","sponsor":"Baptist Health South Florida","startDate":"2022-06-01","conditions":["Meningioma"],"enrollment":24,"completionDate":"2028-05"},{"nctId":"NCT05122546","phase":"PHASE1","title":"CBM588 in Combination With Nivolumab and Cabozantinib for the Treatment of Advanced or Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-11-01","conditions":["Advanced Clear Cell Renal Cell Carcinoma","Advanced Papillary Renal Cell Carcinoma","Advanced Renal Cell Carcinoma","Advanced Sarcomatoid Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Metastatic Papillary Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Metastatic Sarcomatoid Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Unresectable Clear Cell Renal Cell Carcinoma","Unresectable Renal Cell Carcinoma"],"enrollment":31,"completionDate":"2027-01-12"},{"nctId":"NCT05012371","phase":"PHASE2","title":"Lenvatinib With Everolimus Versus Cabozantinib for Second-Line or Third-Line Treatment of Metastatic Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-16","conditions":["Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":90,"completionDate":"2027-10-25"},{"nctId":"NCT04586231","phase":"PHASE3","title":"A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-25","conditions":["Carcinoma, Renal Cell"],"enrollment":747,"completionDate":"2027-02-11"},{"nctId":"NCT07293351","phase":"PHASE1,PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2026-03-26","conditions":["Advanced Renal Cell Carcinoma (RCC)"],"enrollment":234,"completionDate":"2031-11-26"},{"nctId":"NCT04588051","phase":"PHASE2","title":"Cabozantinib in Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stephen Chan Lam","startDate":"2020-11-01","conditions":["HCC"],"enrollment":20,"completionDate":"2028-12-31"},{"nctId":"NCT04091750","phase":"PHASE2","title":"Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Georgetown University","startDate":"2020-03-02","conditions":["Melanoma"],"enrollment":14,"completionDate":"2026-12"},{"nctId":"NCT05048212","phase":"PHASE2","title":"A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-20","conditions":["Brain Metastases","Renal Cell Carcinoma"],"enrollment":20,"completionDate":"2027-01-31"},{"nctId":"NCT07314164","phase":"","title":"Study of Cabozantinib in Participants With Neuroendocrine Tumors Who Have Already Received Prior Treatment","status":"RECRUITING","sponsor":"Ipsen","startDate":"2025-12-17","conditions":["Neuroendocrine Tumors"],"enrollment":150,"completionDate":"2028-12-31"},{"nctId":"NCT05536141","phase":"PHASE1","title":"A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors","status":"RECRUITING","sponsor":"Arcus Biosciences, Inc.","startDate":"2022-10-26","conditions":["Clear Cell Renal Cell Carcinoma","Solid Tumors"],"enrollment":362,"completionDate":"2029-03"},{"nctId":"NCT03647878","phase":"","title":"Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2018-09-24","conditions":["Advanced Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma"],"enrollment":224,"completionDate":"2027-09-30"},{"nctId":"NCT06341712","phase":"PHASE2","title":"Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2024-11-22","conditions":["Osteosarcoma","Osteosarcoma in Children","Osteosarcoma in Adolescents and Young Adults"],"enrollment":10,"completionDate":"2028-06-15"},{"nctId":"NCT05361434","phase":"","title":"A Study of the Effectiveness of Cabozantinib in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma (aRCC) in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2022-09-26","conditions":["Advanced Renal Cell Carcinoma"],"enrollment":311,"completionDate":"2026-11-30"},{"nctId":"NCT04106349","phase":"","title":"Observational Real-life Study of Cabozantinib in Monotherapy or in Combination With Nivolumab in Advanced Renal Cell Carcinoma (RCC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ipsen","startDate":"2020-03-03","conditions":["Advanced or Metastatic Renal Cell Carcinoma"],"enrollment":150,"completionDate":"2027-03-31"},{"nctId":"NCT01068782","phase":"PHASE2","title":"Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse","status":"TERMINATED","sponsor":"Exelixis","startDate":"2010-04","conditions":["Astrocytic Tumors"],"enrollment":19,"completionDate":"2013-10"},{"nctId":"NCT06006013","phase":"PHASE2","title":"Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2025-01-15","conditions":["Locally Advanced Adrenal Cortex Carcinoma","Adrenal Cortical Carcinoma","Stage III Adrenal Cortex Carcinoma","Stage IV Adrenal Cortex Carcinoma AJCC v8","Unresectable Adrenal Cortex Carcinoma"],"enrollment":21,"completionDate":"2028-12-16"},{"nctId":"NCT04339738","phase":"PHASE2","title":"Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-11-04","conditions":["Skin Angiosarcoma","Skin Radiation-Related Angiosarcoma","Visceral Angiosarcoma"],"enrollment":89,"completionDate":"2027-01-21"},{"nctId":"NCT05487859","phase":"PHASE2","title":"Acarbose in Combination With Standard Therapy in Metastatic Renal Cell Carcinoma (RCC)","status":"WITHDRAWN","sponsor":"University of Alabama at Birmingham","startDate":"2025-12-31","conditions":["Kidney Cancer"],"enrollment":0,"completionDate":"2026-12"},{"nctId":"NCT04963283","phase":"PHASE2","title":"Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2021-06-23","conditions":["Colorectal Adenocarcinoma","Colon Cancer","Colon Adenocarcinoma","Rectum Cancer","Rectal Cancer","Rectal Adenocarcinoma","Colorectal Cancer"],"enrollment":48,"completionDate":"2026-02-09"},{"nctId":"NCT06716853","phase":"PHASE1,PHASE2","title":"A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma","status":"TERMINATED","sponsor":"Genenta Science","startDate":"2024-10-22","conditions":["Clear Cell RCC"],"enrollment":10,"completionDate":"2026-01-23"},{"nctId":"NCT05673824","phase":"PHASE2","title":"Effect of Huaier Granule on Nephrotoxicity Associated With Targeted Therapy for Advanced Hepatobiliary Malignancies.","status":"COMPLETED","sponsor":"Fudan University","startDate":"2023-01-03","conditions":["Nephrotoxicity"],"enrollment":76,"completionDate":"2025-12-01"},{"nctId":"NCT07383441","phase":"PHASE3","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","status":"NOT_YET_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2026-06-10","conditions":["Advanced Clear Cell Renal Cell Carcinoma","Metastatic Clear Cell Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8"],"enrollment":718,"completionDate":"2034-01-31"},{"nctId":"NCT03768063","phase":"PHASE3","title":"A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-02-28","conditions":["Cancer"],"enrollment":1000,"completionDate":"2028-07-05"},{"nctId":"NCT03957551","phase":"PHASE1,PHASE2","title":"Cabozantinib and Pembrolizumab for Advanced Metastatic Melanoma","status":"TERMINATED","sponsor":"John Rieth","startDate":"2019-08-27","conditions":["Advanced Metastatic Melanoma"],"enrollment":28,"completionDate":"2025-10-17"},{"nctId":"NCT07077161","phase":"PHASE2","title":"Cabozantinib Dose Skipping as an Alternative to Dose Reductions","status":"RECRUITING","sponsor":"dr. Tom van der Hulle","startDate":"2026-01-01","conditions":["Renal Cell Carcinoma (RCC)"],"enrollment":34,"completionDate":"2028-09-01"},{"nctId":"NCT03798626","phase":"PHASE1","title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-22","conditions":["Colorectal Cancer","Gastroesophageal Cancer","Renal Cell Carcinoma"],"enrollment":167,"completionDate":"2025-02-05"},{"nctId":"NCT05502315","phase":"PHASE2","title":"Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Rana McKay, MD","startDate":"2023-02-02","conditions":["Castration-resistant Prostate Cancer","Metastatic Cancer"],"enrollment":47,"completionDate":"2027-04-12"},{"nctId":"NCT03468218","phase":"PHASE2","title":"Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2018-09-18","conditions":["Metastatic Head and Neck Carcinoma","Paranasal Sinus Squamous Cell Carcinoma","Recurrent Head and Neck Squamous Cell Carcinoma","Recurrent Hypopharyngeal Squamous Cell Carcinoma","Recurrent Laryngeal Squamous Cell Carcinoma","Recurrent Oral Cavity Squamous Cell Carcinoma","Recurrent Oropharyngeal Squamous Cell Carcinoma","Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Hypopharyngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7","Stage IVC Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7","Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7","Unresectable Head and Neck Squamous Cell Carcinoma"],"enrollment":36,"completionDate":"2026-10-29"},{"nctId":"NCT04878029","phase":"PHASE1","title":"Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2021-07-23","conditions":["Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation","Locally Advanced Urothelial Carcinoma","Metastatic Urothelial Carcinoma","Unresectable Urothelial Carcinoma"],"enrollment":32,"completionDate":"2026-12-21"},{"nctId":"NCT04413123","phase":"PHASE2","title":"Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bradley A. McGregor, MD","startDate":"2020-11-05","conditions":["Papillary Renal Cell Carcinoma","Unclassified Renal Cell Carcinoma","Translocation Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Collecting Duct Renal Cell Carcinoma","Renal Cell Carcinoma","Unresectable Advanced Renal Cell Carcinoma","Metastatic Ncc Renal Cell Carcinoma"],"enrollment":60,"completionDate":"2026-12-20"},{"nctId":"NCT03539822","phase":"PHASE1,PHASE2","title":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2018-10-22","conditions":["Gastric Cancer","Esophageal Adenocarcinoma","Hepatocellular Carcinoma","Colorectal Cancer"],"enrollment":117,"completionDate":"2029-06-30"},{"nctId":"NCT06835972","phase":"PHASE1,PHASE2","title":"A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-02-14","conditions":["Metastatic Renal Cell Carcinoma","Translocation Renal Cell Carcinoma"],"enrollment":43,"completionDate":"2027-02"},{"nctId":"NCT04876456","phase":"PHASE2","title":"A Phase II Trial of Cabozantinib With Patients With Refractory GCTs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer King","startDate":"2021-06-10","conditions":["Germ Cell Tumor","Seminoma","Non-seminomatous Germ Cell Tumor","Ovarian Germ Cell Tumor"],"enrollment":50,"completionDate":"2027-01"},{"nctId":"NCT06726421","phase":"PHASE3","title":"Systemic Therapy Alone or With Stereotactic Body Radiotherapy for Oligometastatic Kidney Cancer (STROKER Study)","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-09-18","conditions":["Renal Cell Carcinoma (Kidney Cancer)","Kidney Cancer Metastatic","Renal Cell Carcinoma Metastatic"],"enrollment":252,"completionDate":"2033-09-30"},{"nctId":"NCT05327686","phase":"PHASE2","title":"Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial","status":"RECRUITING","sponsor":"NRG Oncology","startDate":"2023-02-01","conditions":["Metastatic Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Unresectable Renal Cell Carcinoma"],"enrollment":240,"completionDate":"2028-06-15"},{"nctId":"NCT05092373","phase":"PHASE1","title":"Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-04-29","conditions":["Advanced Breast Carcinoma","Advanced Endometrial Carcinoma","Advanced Fallopian Tube Carcinoma","Advanced Hepatocellular Carcinoma","Advanced Malignant Abdominal Neoplasm","Advanced Malignant Female Reproductive System Neoplasm","Advanced Malignant Thoracic Neoplasm","Advanced Ovarian Carcinoma","Advanced Primary Peritoneal Carcinoma","Advanced Renal Cell Carcinoma","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Anatomic Stage IV Breast Cancer AJCC v8","Malignant Abdominal Neoplasm","Malignant Solid Neoplasm","Metastatic Breast Carcinoma","Metastatic Endometrial Carcinoma","Metastatic Fallopian Tube Carcinoma","Metastatic Hepatocellular Carcinoma","Metastatic Malignant Abdominal Neoplasm","Metastatic Malignant Female Reproductive System Neoplasm","Metastatic Malignant Thoracic Neoplasm","Metastatic Ovarian Carcinoma","Metastatic Primary Peritoneal Carcinoma","Metastatic Renal Cell Carcinoma","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8","Prognostic Stage IV Breast Cancer AJCC v8","Stage III Fallopian Tube Cancer AJCC v8","Stage III Hepatocellular Carcinoma AJCC v8","Stage III Ovarian Cancer AJCC v8","Stage III Primary Peritoneal Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage III Uterine Corpus Cancer AJCC v8","Stage IIIA Fallopian Tube Cancer AJCC v8","Stage IIIA Hepatocellular Carcinoma AJCC v8","Stage IIIA Ovarian Cancer AJCC v8","Stage IIIA Primary Peritoneal Cancer AJCC v8","Stage IIIA Uterine Corpus Cancer AJCC v8","Stage IIIA1 Fallopian Tube Cancer AJCC v8","Stage IIIA1 Ovarian Cancer AJCC v8","Stage IIIA2 Fallopian Tube Cancer AJCC v8","Stage IIIA2 Ovarian Cancer AJCC v8","Stage IIIB Fallopian Tube Cancer AJCC v8","Stage IIIB Hepatocellular Carcinoma AJCC v8","Stage IIIB Ovarian Cancer AJCC v8","Stage IIIB Primary Peritoneal Cancer AJCC v8","Stage IIIB Uterine Corpus Cancer AJCC v8","Stage IIIC Fallopian Tube Cancer AJCC v8","Stage IIIC Ovarian Cancer AJCC v8","Stage IIIC Primary Peritoneal Cancer AJCC v8","Stage IIIC Uterine Corpus Cancer AJCC v8","Stage IIIC1 Uterine Corpus Cancer AJCC v8","Stage IIIC2 Uterine Corpus Cancer AJCC v8","Stage IV Fallopian Tube Cancer AJCC v8","Stage IV Hepatocellular Carcinoma AJCC v8","Stage IV Ovarian Cancer AJCC v8","Stage IV Primary Peritoneal Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IV Uterine Corpus Cancer AJCC v8","Stage IVA Fallopian Tube Cancer AJCC v8","Stage IVA Hepatocellular Carcinoma AJCC v8","Stage IVA Ovarian Cancer AJCC v8","Stage IVA Primary Peritoneal Cancer AJCC v8","Stage IVA Uterine Corpus Cancer AJCC v8","Stage IVB Fallopian Tube Cancer AJCC v8","Stage IVB Hepatocellular Carcinoma AJCC v8","Stage IVB Ovarian Cancer AJCC v8","Stage IVB Primary Peritoneal Cancer AJCC v8","Stage IVB Uterine Corpus Cancer AJCC v8"],"enrollment":43,"completionDate":"2026-09-01"},{"nctId":"NCT00596648","phase":"PHASE1,PHASE2","title":"A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Exelixis","startDate":"2008-02-12","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":92,"completionDate":"2012-08-02"},{"nctId":"NCT03541902","phase":"PHASE2","title":"Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-15","conditions":["Malignant Neoplasms of Urinary Tract","Renal Cell Carcinoma","Chromophobe Renal Cell Carcinoma","Metastatic Renal Cell Carcinoma","Papillary Renal Cell Carcinoma","Renal Cell Carcinoma Associated With Xp11.2 Translocations/TFE3 Gene Fusions","Sarcomatoid Renal Cell Carcinoma","Stage IV Renal Cell Cancer AJCC v8","Unclassified Renal Cell Carcinoma"],"enrollment":32,"completionDate":"2027-07-31"},{"nctId":"NCT05613413","phase":"PHASE2","title":"A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2022-12-28","conditions":["Metastatic Squamous Non-Small Cell Lung Carcinoma"],"enrollment":36,"completionDate":"2028-09"},{"nctId":"NCT01995058","phase":"PHASE2","title":"Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC","status":"TERMINATED","sponsor":"Exelixis","startDate":"2014-02","conditions":["Prostate Cancer","Castration Resistant Prostate Cancer","Prostatic Neoplasms"],"enrollment":54,"completionDate":"2014-11"},{"nctId":"NCT04820179","phase":"PHASE2","title":"Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Arizona","startDate":"2021-10-12","conditions":["Pancreatic Cancer","Metastatic Pancreatic Cancer"],"enrollment":30,"completionDate":"2026-01-31"},{"nctId":"NCT04200443","phase":"PHASE2","title":"Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2020-01-14","conditions":["Metastatic Leiomyosarcoma","Metastatic Soft Tissue Sarcoma","Stage III Uterine Corpus Leiomyosarcoma AJCC v8","Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8","Stage IIIB Uterine Corpus Leiomyosarcoma AJCC v8","Stage IIIC Uterine Corpus Leiomyosarcoma AJCC v8","Stage IV Uterine Corpus Leiomyosarcoma AJCC v8","Stage IVA Uterine Corpus Leiomyosarcoma AJCC v8","Stage IVB Uterine Corpus Leiomyosarcoma AJCC v8","Unresectable Leiomyosarcoma","Unresectable Soft Tissue Sarcoma"],"enrollment":72,"completionDate":"2026-09-10"},{"nctId":"NCT04022343","phase":"PHASE2","title":"Neoadjuvant Cabozantinib in Treating Patients With Locally Advanced Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-08-06","conditions":["Clear Cell Renal Cell Carcinoma","Renal Cell Carcinoma","Stage III Renal Cell Cancer AJCC v8"],"enrollment":22,"completionDate":"2026-03-01"},{"nctId":"NCT06026410","phase":"PHASE1","title":"KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2023-10-18","conditions":["Solid Tumors With HRAS Alterations","Non Small Cell Lung Cancer (NSCLC)","Colorectal Cancer (CRC)","Pancreatic Ductal Adenocarcinoma (PDAC)","Clear Cell Renal Cell Carcinoma (ccRCC)","Renal Cell Carcinoma (Kidney Cancer)","Non Clear Cell Renal Cell Carcinoma (nccRCC)"],"enrollment":300,"completionDate":"2027-04"},{"nctId":"NCT05100082","phase":"","title":"Survey of Cabozantinib Tablets Used To Treat People With Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-11-17","conditions":["Hepatocellular Cancer"],"enrollment":263,"completionDate":"2025-11-30"},{"nctId":"NCT01658878","phase":"PHASE1,PHASE2","title":"An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2012-10-30","conditions":["Hepatocellular Carcinoma"],"enrollment":657,"completionDate":"2024-11-12"},{"nctId":"NCT04471428","phase":"PHASE3","title":"Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-01","conditions":["Carcinoma, Non-Small-Cell Lung"],"enrollment":366,"completionDate":"2025-01-17"},{"nctId":"NCT05039281","phase":"PHASE1,PHASE2","title":"Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-09-23","conditions":["Recurrent Glioblastoma","Recurrent Gliosarcoma"],"enrollment":6,"completionDate":"2027-12-31"},{"nctId":"NCT04446117","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2020-10-19","conditions":["Metastatic Prostate Cancer","Prostate Adenocarcinoma"],"enrollment":575,"completionDate":"2026-10-16"},{"nctId":"NCT04631744","phase":"PHASE2","title":"Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2021-03-03","conditions":["Prostate Cancer"],"enrollment":4,"completionDate":"2025-11-09"},{"nctId":"NCT01639508","phase":"PHASE2","title":"Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-07","conditions":["Non-Small Cell Lung Cancer"],"enrollment":86,"completionDate":"2026-07"},{"nctId":"NCT03755791","phase":"PHASE3","title":"Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2018-06-10","conditions":["Hepatocellular Carcinoma"],"enrollment":837,"completionDate":"2026-07-31"},{"nctId":"NCT05579847","phase":"","title":"Feasibility of a Smart-Phone App for Patients With Advanced Renal Cell Carcinoma Undergoing Combination Immunotherapy","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-10-19","conditions":["Renal Cell Carcinoma Stage IV"],"enrollment":20,"completionDate":"2024-11-04"},{"nctId":"NCT04204850","phase":"PHASE2","title":"Cabozantinib to Treat Recurrent Liver Cancer Post Transplant","status":"RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2020-08-07","conditions":["Hepatocellular Carcinoma","Recurrent Cancer","Liver Transplant"],"enrollment":20,"completionDate":"2026-06-30"},{"nctId":"NCT05263050","phase":"PHASE2","title":"Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors","status":"RECRUITING","sponsor":"Fox Chase Cancer Center","startDate":"2022-01-21","conditions":["Metastatic Renal Cell Carcinoma","Clear-cell Metastatic Renal Cell Carcinoma","Neuroendocrine Tumors","Carcinoid Tumor"],"enrollment":111,"completionDate":"2027-02"},{"nctId":"NCT03963206","phase":"PHASE4","title":"Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2019-09-09","conditions":["Hepatocellular Carcinoma"],"enrollment":110,"completionDate":"2021-10-07"},{"nctId":"NCT01708954","phase":"PHASE2","title":"Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2013-02-13","conditions":["Recurrent Lung Non-Small Cell Carcinoma","Stage IV Lung Non-Small Cell Cancer AJCC v7"],"enrollment":125,"completionDate":"2026-03-18"},{"nctId":"NCT05287464","phase":"","title":"International Multicentric Study ARON-1","status":"RECRUITING","sponsor":"Hospital of Macerata","startDate":"2022-03-10","conditions":["Metastatic Renal Cell Carcinoma (mRCC)"],"enrollment":1220,"completionDate":"2027-09-30"},{"nctId":"NCT04412629","phase":"PHASE2","title":"Cabozantinib in High Grade Neuroendocrine Neoplasms","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2020-11-24","conditions":["High Grade Neuroendocrine Neoplasms"],"enrollment":35,"completionDate":"2026-09-30"},{"nctId":"NCT04116541","phase":"PHASE2","title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","status":"RECRUITING","sponsor":"Centre Leon Berard","startDate":"2020-01-28","conditions":["Malignant Solid Tumor"],"enrollment":455,"completionDate":"2026-11"},{"nctId":"NCT05038839","phase":"PHASE1","title":"Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2022-02-09","conditions":["Advanced Malignant Solid Neoplasm","Refractory Malignant Solid Neoplasm"],"enrollment":44,"completionDate":"2026-06-03"},{"nctId":"NCT05052723","phase":"PHASE2","title":"Cabozantinib and Pembrolizumab in Metastatic Pancreas","status":"COMPLETED","sponsor":"Joseph Kim","startDate":"2022-01-04","conditions":["Pancreatic Cancer"],"enrollment":21,"completionDate":"2024-11-05"},{"nctId":"NCT06132945","phase":"PHASE1","title":"A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the Brain","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-11-10","conditions":["Metastatic Renal Cell Carcinoma","Brain Metastases"],"enrollment":2,"completionDate":"2027-11"},{"nctId":"NCT06156410","phase":"PHASE1","title":"Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas","status":"RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-10-24","conditions":["Ewing Sarcoma","Osteosarcoma","Sarcomas"],"enrollment":30,"completionDate":"2028-11"},{"nctId":"NCT04551430","phase":"PHASE2","title":"Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-01-05","conditions":["Metastatic Soft-tissue Sarcoma"],"enrollment":105,"completionDate":"2029-02-01"},{"nctId":"NCT04477512","phase":"PHASE1","title":"Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2021-02-19","conditions":["Metastatic Hormone Refractory Prostate Cancer"],"enrollment":18,"completionDate":"2025-09-10"},{"nctId":"NCT06698250","phase":"PHASE2","title":"Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)","status":"RECRUITING","sponsor":"Anwaar Saeed","startDate":"2024-12-18","conditions":["Hepatocellular Carcinoma"],"enrollment":40,"completionDate":"2027-04-30"},{"nctId":"NCT05613894","phase":"PHASE1","title":"Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"University of Utah","startDate":"2023-07-14","conditions":["Metastatic Castration-resistant Prostate Cancer"],"enrollment":33,"completionDate":"2028-05-01"}],"_emaApprovals":[{"date":"2014-03-21","status":"Authorised","company":"TMC Pharma Services Ltd"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Oral","formulation":"Capsule, Tablet","formulations":[{"form":"CAPSULE","route":"ORAL","productName":"COMETRIQ"},{"form":"TABLET","route":"ORAL","productName":"CABOMETYX"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000186139","MMSL":"194795","NDDF":"014768","UNII":"1C39JW444G","VUID":"4032025","CHEBI":"CHEBI:72319","VANDF":"4032025","INN_ID":"9297","RXNORM":"1363267","UMLSCUI":"C3181682","chemblId":"CHEMBL2103868","ChEMBL_ID":"CHEMBL2105717","KEGG_DRUG":"D10062","DRUGBANK_ID":"DB08875","PUBCHEM_CID":"25102847","SNOMEDCT_US":"718844003","IUPHAR_LIGAND_ID":"5887","SECONDARY_CAS_RN":"1140909-48-3","MESH_SUPPLEMENTAL_RECORD_UI":"C558660"},"formularyStatus":[],"originalProduct":{"form":"TABLET","route":"ORAL","company":"Exelixis, Inc.","brandName":"CABOMETYX","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2012-","companyName":"Exelixis","relationship":"Original Developer"},{"period":"2014","companyName":"TMC Pharma Services Ltd","relationship":"EMA Licensee"},{"period":"2020","companyName":"Takeda Pharmaceutical Company Limited","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"FDA label","halfLife":"55 hours"},"publicationCount":23,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-08 13:58:11.654237+00","atcClassification":{"source":"DrugCentral","atcCode":"L01EX07","allCodes":["L01EX07"]},"biosimilarFilings":[],"originalDeveloper":"Exelixis","recentPublications":[{"date":"2026 Mar 14","pmid":"41826714","title":"A novel cabozantinib formulation with improved safety and bioavailability: preclinical validation in rats.","journal":"Cancer chemotherapy and pharmacology"},{"date":"2026 Jan","pmid":"41555735","title":"Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.","journal":"Health technology assessment (Winchester, England)"},{"date":"2022","pmid":"36743424","title":"Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma.","journal":"Kidney cancer (Clifton, Va.)"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"Exelixis","companyId":"exelixis","modality":"Small molecule","firstApprovalDate":"2012","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"8497284","territory":"US","patent_type":null,"expiry_date":"2024-09-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7579473","territory":"US","patent_type":null,"expiry_date":"2026-08-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11091440","territory":"US","patent_type":null,"expiry_date":"2030-01-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11098015","territory":"US","patent_type":null,"expiry_date":"2030-01-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11091439","territory":"US","patent_type":null,"expiry_date":"2030-01-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8877776","territory":"US","patent_type":null,"expiry_date":"2030-10-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10034873","territory":"US","patent_type":null,"expiry_date":"2031-07-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10039757","territory":"US","patent_type":null,"expiry_date":"2031-07-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9717720","territory":"US","patent_type":null,"expiry_date":"2032-02-10T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11298349","territory":"US","patent_type":null,"expiry_date":"2032-02-10T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9724342","territory":"US","patent_type":null,"expiry_date":"2033-07-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":3,"lastValidatedAt":"2026-04-20T00:29:47.986048+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}